Article

Construction of 2DE Patterns of Plasma Proteins: Aspect of Potential Tumor Markers

Stanislav Naryzhny 1,2,*, Natalia Ronzhina 2, Elena Zorina 1, Fedor Kabachenko 3, Nikolay Klopov 2 and Victor Zgoda 1

1 Institute of Biomedical Chemistry, Pogodinskaya, 10, 119121 Moscow, Russia
2 Petersburg Institute of Nuclear Physics (PNPI) of National Research Center “Kurchatov Institute”, 188300 Gatchina, Russia
3 Institute of Biomedical Systems and Biotechnology, Peter the Great St. Petersburg Polytechnic University, 195251 St. Petersburg, Russia

* Correspondence: snaryzhny@mail.ru; Tel.: +7-911-176-4453

Abstract: The use of tumor markers aids in the early detection of cancer recurrence and prognosis. There is a hope that they might also be useful in screening tests for the early detection of cancer. Here, the question of finding ideal tumor markers, which should be sensitive, specific, and reliable, is an acute issue. Human plasma is one of the most popular samples as it is commonly collected in the clinic and provides noninvasive, rapid analysis for any type of disease including cancer. Many efforts have been applied in searching for “ideal” tumor markers, digging very deep into plasma proteomes. The situation in this area can be improved in two ways—by attempting to find an ideal single tumor marker or by generating panels of different markers. In both cases, proteomics certainly plays a major role. There is a line of evidence that the most abundant, so-called “classical plasma proteins”, may be used to generate a tumor biomarker profile. To be comprehensive these profiles should have information not only about protein levels but also proteoform distribution for each protein. Initially, the profile of these proteins in norm should be generated. In our work, we collected bibliographic information about the connection of cancers with levels of “classical plasma proteins”. Additionally, we presented the proteoform profiles (2DE patterns) of these proteins in norm generated by two-dimensional electrophoresis with mass spectrometry and immunodetection. As a next step, similar profiles representing protein perturbations in plasma produced in the case of different cancers will be generated. Additionally, based on this information, different test systems can be developed.

Keywords: plasma; biomarker; proteomics; 2DE; proteoform; pattern

1. Introduction

In a broad sense, tumor biomarkers are components that are either produced directly or indirectly because of a tumor. Moreover, these biomarkers can be common cellular products that are overproduced by cancer cells or the products of genes that are expressed only during malignant transformation. Thus, a tumor marker that is present in significant quantities indicates the presence of cancer. The marker can be present inside the tumor or enter the bloodstream [1,2]. This point is fundamentally important, as it allows the noninvasive examination and treatment of patients with various malignant neoplasms. The list of biochemical tumor markers known today is large [2]. Although some of these biomarkers have been successfully used in treatment, none of them fully satisfy the so-called “ideal marker”, which should be highly sensitive, specific, reliable with high predictive value, and correlate with the stages of tumor development [3].

Therefore, the search for new markers continues. Here, multi-omics technologies such as genomics, transcriptomics, and metabolomics are very important, but proteomics plays a central role since tumor biomarkers are mostly proteins. From a proteomic point of view, the search is based on a comparative analysis of proteomes. These proteomes are
from body fluids (blood plasma, cerebrospinal fluid, saliva, urine, etc.) or tissues. Here, human plasma is one of the most popular clinical samples as it provides noninvasive, rapid analysis for any type of disease. A special human plasma proteome project (HPPP) project was initiated in 2002 (https://www.hupo.org/plasma-proteome-project accessed on 10 September 2022). Now, this initiative has achieved great success in plasma protein analysis (http://plasmaproteomedatabase.org/index.html accessed on 10 September 2022) [4,5]. One of the main advantages of using plasma samples is that only a minimally invasive assay such as a routine blood test analysis is required. To the greatest extent, this certainly concerns the hematopoietic organs (for instance, the major human plasma proteins are synthesized mostly in the liver), but also applies to other tissues, and even the brain, which is separated by the blood–brain barrier. It is expected that the blood plasma proteome should reflect, to varying degrees, changes in cellular proteomes caused by diseases. In recent years, biomarker selection guidelines have been developed [6–10]. Here, the classical proteomic approaches are used: two-dimensional electrophoresis (2DE), immunodetection, and mass spectrometry (MS), which have many methodological options that allow highly productive analysis individually or together in different combinations. Electrophoretic separation of plasma proteins offers a valuable diagnostic tool, as well as a way to monitor clinical progress [11]. MS measures, with high accuracy, the masses of peptides obtained by specific hydrolysis of proteins and is very specific. This approach was applied for detecting ovarian cancer (OC) based on just MS-spectra [12]. In addition, MS-based proteomics can detect and quantify protein variants—proteoforms [13]. Ideally, MS-based proteomics can analyze a whole proteome [14–16]. A rapid, robust, and reproducible shotgun plasma proteomics workflow was developed to produce “plasma proteome profiles” [14,17].

Accordingly, there are several directions for proteomics to develop ideal oncomarkers. First, we can go deep—find highly specific proteoforms/oncomarkers secreted by a tumor in low abundancy. Second, go wide—select, and analyze a panel of multiple proteins/oncomarkers. Third, combine these approaches. There are already some examples of generation from such panels [18]. This strategy can be applied to solid or liquid biopsies depending on the real situation. Here, the question arises about how to select these oncomarkers, as the concentration range of putative oncomarkers in plasma is very wide. The plasma proteome is the most complete version of the whole human proteome. In addition to the “classical plasma proteins”, it contains tissue proteins plus numerous individual immunoglobulins [19,20]. In clinics, a lot of information about the health state is obtained by analysis of blood proteins. Accordingly, in diagnosis and therapeutic monitoring, human plasma proteome analysis is a promising solution. The major protein, albumin, accounts for ~50% of the mass of all proteins. Nine proteins (IgG, apolipoprotein A1, apolipoprotein A2, transferrin, fibrinogen, haptoglobin, alpha1-antitrypsin, transthyretin) make up 40%, another 12 make up the next 9%, and the rest only 1%. Accordingly, it is common practice to remove the most abundant proteins (deplete) before deep proteomics analysis of plasma [21].

Two-dimensional electrophoresis analysis of human plasma proteins has a long history, where, possibly, the input of L. Anderson and N.G. Anderson is most impressive [22–24]. There are many publications where the 2DE image of plasma proteins was used as a specific profile for testing the cancer-related changes in the human body [25–29]. However, if we are going to decipher the whole panel of plasma proteins as a combined tumor biomarker, we need to obtain reliable data about every protein in connection to its response during the malignancy process. Previously, we started to collect information about the proteoform profiles of different cellular proteins into a database “2DE pattern” using our original approaches [30]. These approaches are time consuming and labor intensive but allow the presentation of panoramic data about different proteoforms and could be very useful in biomarker studies. Here, as a next step in searching for specific oncomarkers, we produced 2DE profiles for the human plasma proteins. The most abundant, “classical plasma proteins” were selected as they are detected reliably by common proteomics methods.
2. Results

In our study, using classical 2DE, sectional 2DE, and semi-virtual 2DE in combination with liquid chromatography–electrospray ionization tandem mass spectrometry (LC ESI-MS/MS), we generated 2DE patterns for the most abundant plasma proteins. In Figure 1, these 2DE images of plasma proteins are presented. The 2DE patterns of more than 100 reliable and confidently detected sets (Supplementary Tables S1 and S2) are presented in Supplementary Figure S1. We also collected data from the literature about the possibilities of using these plasma proteins as cancer biomarkers (Table 1) [20,31]. The detailed information about these proteins and the 2DE patterns of plasma proteins in norm generated in our experiments are described below and in the Supplementary File.

Figure 1. Two-dimensional electrophoresis image of depleted plasma proteins taken for the sectional analysis. (a) A classical annotated 2DE image of plasma proteins; (b) a sectional analysis of the gel presented in (a). The stained gel was divided into the sections with the predetermined coordinates, and each section was treated and analyzed by LC ESI-MS/MS (see Materials and Methods, Section 4.2, 2DE); (c) a semi-virtual 2DE of the major plasma proteins. The plasma proteins were separated by isoelectrophocusing (IEF), using the 18-cm Immobiline DryStrip 3–11 NL. The strip was cut to 36 equal sections, and each section was treated and analyzed by LC ESI-MS/MS (see Materials and Methods, Section 4.2, 2DE). According to the abundance (emPAI) of each protein in the sections, the graph was plotted. The ball size is proportional to the protein emPAI in each section.
Table 1. The most abundant plasma proteins related to cancer. Concentration (µg/mL) is presented according to [16] if otherwise not shown. Abundance (emPAI) was calculated according to data from the semi-virtual 2DE (Supplementary Table S1). In the column “Cancer”, the references for cancer-related data are shown (the details are in the Supplementary File).

| N. | UniProt ID (UniProt) | UniProt Name (Gene) | pI/Mw | Level µg/mL | EmPAI | Cancer |
|----|---------------------|---------------------|-------|-------------|-------|--------|
| 1  | P02763              | A1AG1_HUMAN         |       |             |       |        |
| 2  | P19652              | A1AG2_HUMAN         |       |             |       |        |
| 3  | P01009              | A1AT_HUMAN          |       |             |       |        |
| 4  | P04217              | A1BG_HUMAN          |       |             |       |        |
| 5  | P01023              | A2MG_HUMAN          |       |             |       |        |
| 6  | P08697              | A2AP_HUMAN          |       |             |       |        |
| 7  | P02750              | A2GL_HUMAN          |       |             |       |        |
| 8  | P01011              | AACT_HUMAN          |       |             |       |        |
| 9  | Q15848              | ADIPO_HUMAN         |       |             |       |        |
| 10 | P43652              | AFAM_HUMAN          |       |             |       |        |
| 11 | P02768              | ALBU_HUMAN          |       |             |       |        |
| 12 | P02760              | AMBP_HUMAN          |       |             |       |        |
| 13 | P01019              | ANGT_HUMAN          |       |             |       |        |
| 14 | P01008              | ANT3_HUMAN          |       |             |       |        |
| 15 | P02647              | APOA1_HUMAN         |       |             |       |        |
| 16 | P02652              | APOA2_HUMAN         |       |             |       |        |
| 17 | P06727              | APOA4_HUMAN         |       |             |       |        |
| 18 | P04114              | APOB_HUMAN          |       |             |       |        |
| 19 | P02654              | APOC1_HUMAN         |       |             |       |        |
| 20 | P02655              | APOC2_HUMAN         |       |             |       |        |
| 21 | P02656              | APOC3_HUMAN         |       |             |       |        |
| 22 | P05090              | APOD_HUMAN          |       |             |       |        |
| 23 | P02649              | APOE_HUMAN          |       |             |       |        |
| 24 | Q13790              | APOF_HUMAN          |       |             |       |        |
| 25 | P02749              | APOH_HUMAN          |       |             |       |        |
| 26 | O95445              | APOM_HUMAN          |       |             |       |        |
| 27 | P02747              | C1QC_HUMAN          |       |             |       |        |
| 28 | P00736              | C1R_HUMAN           |       |             |       |        |
| 29 | P09871              | C1S_HUMAN           |       |             |       |        |

Note: Some entries have been abbreviated for brevity.
| N. | UniProt ID (UniProt) | UniProt Name (Gene) | pl/Mw | Level µg/mL | EmPAI | Cancer |
|----|---------------------|---------------------|-------|-------------|-------|--------|
| 30 | P05156 CFA1_HUMAN   | Complement factor I (CFI) | 7.38/63,487 | 0.006 | 11.9 | 49, 114 |
| 31 | P00751 CFAB_HUMAN   | Complement factor B (CFB) | 6.66/83,001 | 95 [115] | 1.14 | 58, 69, 116, 117 |
| 32 | P00746 CFAD_HUMAN   | Complement factor D (CFD) | 6.85/24,405 | 2.9 | 7.1 | 118 |
| 33 | P08603 CFAH_HUMAN   | Complement factor H (CFH) | 6.12/137,053 | 57 | 0.24 | 32, 119–121 |
| 34 | P06681 CO2_HUMAN    | Complement C2 (C2) | 7.57/81,085 | 35 | 20.5 | 32 |
| 35 | P01024 CO3_HUMAN    | Complement C3 (C3) | 6.00/184,951 | 260 | 31.1 | 58, 93, 116, 122–125 |
| 36 | P0COL4 CO4A_HUMAN   | Complement C4-A (C4A) | 6.60/190,534 | 63 [115] | 36.3 | 52, 124, 125 |
| 37 | P0COL5 CO4B_HUMAN   | Complement C4-B (C4B) | 6.83/190,500 | 90 | 37.8 | 124, 125 |
| 38 | P01031 CO5_HUMAN    | Complement C5 (C5) | 6.07/186,341 | 95 | 35.7 | 69, 126 |
| 39 | P13671 CO6_HUMAN    | Complement C6 (C6) | 6.17/102,412 | 3.7 | 15.7 | 32, 52 |
| 40 | P10643 CO7_HUMAN    | Complement C7 (C7) | 6.09/91,115 | 2.6 | 17 | 69, 127 |
| 41 | P02748 CO9_HUMAN    | Complement component C9 (C9) | 5.42/60,979 | 5.2 | 11.8 | 128–130 |
| 42 | P00915 CAH1_HUMAN   | Carbonic anhydrase (CA1) | 6.63/28,739 | 0.59 | 2.5 | 131, 132 |
| 43 | P08185 CBG_HUMAN    | Corticosteroid-binding globulin (SERPINA6) | 5.64/42,639 | 1.2 | 27.9 | 133 |
| 44 | P15169 CBPN_HUMAN   | Carboxypeptidase N catalytic chain (CPN1) | 6.88/50,034 | 0.72 | 6.4 | 134 |
| 45 | P08571 CD14_HUMAN   | Monocyte differentiation antigen CD14 (CD14) urinary form | 5.58/37,215 | 0.42 | 4.5 | 135, 136 |
| 46 | P00450 CERU_HUMAN   | Ceruloplasmin (CP) | 5.41/120,085 | 86 | 86.7 | 34, 54, 137–142 |
| 47 | P06276 CHLE_HUMAN   | Cholinesterase (BCHE) | 6.33/65,084 | 0.17 | 2.97 | 143 |
| 48 | P10909 CLUS_HUMAN   | Clusterin (CLU) | 5.89/50,063 | 25 | 29.9 | 32, 52, 58, 69, 144–149 |
| 49 | Q96KN2 CNDP1_HUMAN | Beta-Ala-His dipeptidase (CNDP1) | 5.08/53,864 | 0.23 | 2.7 | 150–153 |
| 50 | P22792 CPN2_HUMAN   | Carboxypeptidase N subunit 2 (CPN2) | 5.54/58,227 | 2 | 6.1 | 32 |
| 51 | P02741 CRP_HUMAN    | C-reactive protein (CRP) | 5.28/23,047 | 0.26 | 1.0 | 154, 155 |
| 52 | Q16610 ECM1_HUMAN   | Extracellular matrix protein 1 (ECM1) | 6.19/58,812 | 0.77 | 9.6 | 156–158 |
| 53 | P23142 FBLN1_HUMAN | Fibulin-1 (FBLN1) | 5.03/74,291 | 0.62 | 11.8 | 159–163 |
| 54 | O75636 FCN3_HUMAN   | Ficolin-3 (FCN3) | 6.22/30,354 | 1 | 11.8 | 164–168 |
| 55 | P02765 FETUA_HUMAN | Alpha-2-HS-glycoprotein (AHSG) | 4.53/30,238 | 82 | 30.6 | 169, 170 |
| 56 | Q9UGM5 FETUB_HUMAN | Fetuin-B (FETUB) | 6.52/40,488 | 0.27 | 1.8 | 171 |
| 57 | P02671 FIBA_HUMAN   | Fibrinogen alpha chain (FGA) | 5.79/91,359 | 0.13 | 10.9 | 32, 69, 172, 173 |
| 58 | P02675 FIBB_HUMAN   | Fibrinogen beta chain (FGB) | 7.95/50,763 | 130 | 62.5 | 32, 173, 174 |
| 59 | P02679 FIBG_HUMAN   | Fibrinogen gamma chain (FGG) | 5.24/48,483 | 98 | 39.2 | 32, 69, 175–178 |
| N. | UniProt ID (UniProt) | UniProt Name (Gene) | pI/Mw  | Leve µg/mL | EmPAI  | Cancer       |
|---|---------------------|---------------------|--------|------------|--------|--------------|
| 60 | P02751 FINC_HUMAN   | Fibronectin (FN1)   | 5.25/269,259 | 20 | 14.1 | [48,94,179–182] |
| 61 | P06396 GELS_HUMAN   | Plasma gelsolin (GSN) | 5.72/82,959 | 16 | 23.4 | [166,183,184] |
| 62 | P22352 GPX3_HUMAN   | Glutathione peroxidase 3 (GPX3) | 7.85/23,464 | 10 | 11.7 | [185] |
| 63 | P69905 HBA_HUMAN    | Hemoglobin subunit alpha (HBA1) | 8.73/15,126 | 41 | 1129 | [54] |
| 64 | P68871 HBB_HUMAN    | Hemoglobin subunit beta (HBB) | 6.81/15,867 | 30 | 847.0 | [54,186] |
| 65 | P02790 HEMO_HUMAN   | Hemopexin (HPX)     | 6.43/49,295 | 180 | 165.0 | [177,187–189] |
| 66 | P05546 HEP2_HUMAN   | Heparin Cofactor 2 (SERPIND1) | 6.26/54,960 | 4.3 | 43.0 | [58,189–192] |
| 67 | P00738 HPT_HUMAN    | Haptoglobin (Zonulin) (HP) haptoglobin alpha 1 chain haptoglobin alpha 2 chain haptoglobin beta chain | 6.13/43,349 5.23/93,555 5.57/15,946 6.32/27,265 | 210 | 323.0 | [166,193–199] |
| 68 | P00739 HPTR_HUMAN   | Haptoglobin-related protein (HPR) | 6.63/39,030 | 41 [200] | 105.0 | [201] |
| 69 | P04196 HRG_HUMAN    | Histidine-rich glycoprotein (HRG) | 7.03/57,660 | 35 | 24.0 | [202,203] |
| 70 | P05155 IC1_HUMAN    | Plasma protease C1 inhibitor (SERPING1) | 5.97/52,843 | 12 | 9.4 | [204,205] |
| 71 | P19827 ITIH1_HUMAN  | Inter-alpha-trypsin inhibitor heavy chain H1 (ITIh1) | 6.33/71,415 | 24 | 25.0 | [29,206–210] |
| 72 | Q06033 ITIH3_HUMAN  | Inter-alpha-trypsin inhibitor heavy chain H3 (ITIh3) | 5.01/69,360 | 2 | 7.7 | [207] |
| 73 | Q14624 ITIH4_HUMAN  | Inter-alpha-trypsin inhibitor heavy chain H4 (ITIh4) | 5.92/70,586 | 42 | 41.6 | [29,207] |
| 74 | P29622 KAIN_HUMAN   | Kallistatin (SERPINA4) | 7.88/46,355 | 1.1 | 81.8 | [211] |
| 75 | P01042 KNG1_HUMAN   | Kininogen 1 (KNG1) | 6.23/69,897 | 28 | 7.7 | [212–214] |
| 76 | P04180 LCAT_HUMAN   | Phosphatidylcholine-sterol acyltransferase (LCAT) | 5.71/47,084 | 0.22 | 1.8 | [171] |
| 77 | P51884 LUM_HUMAN    | Lumican (LUM) | 6.17/36,661 | 4 | 6.4 | [166,215–217] |
| 78 | P11226 MBL2_HUMAN   | Mannose-binding protein C (MBL2) | 5.40/24,021 | 0.07 | 6.4 | [171,218,219] |
| 79 | P36955 PEDF_HUMAN   | Pigment epithelium-derived factor (SERPINF1) | 5.90/44,388 | 7.2 | 14.5 | [220] |
| 80 | Q96PD5 PGRP2_HUMAN  | N-acetylmuramoyl-L-alanine amidase (PGLYRP2) | 7.64/59,980 | 14 | 4.0 | [171,221,222] |
| 81 | P80108 PHLD_HUMAN   | Phosphatidylinositol-glycan-specific phospholipase D (GPLD1) | 5.78/89,811 | 4 | 3.7 | [32,223,224] |
| 82 | P00747 PLMN_HUMAN   | Plasminogen (PLG) Plasmin heavy chain A Angiostatin Plasmin heavy chain A, short form Plasmin light chain | 7.08/88,432 6.79/63,245 8.30/44,053 7.44/54,341 7.67/25,205 | 25 | 81.0 | [225,226] |
| 83 | P27169 PON1_HUMAN   | Serum paraoxonase/arylesterase 1 (PON1) | 5.08/39,600 | 7.7 | 43.4 | [79,227–232] |
Table 1. Cont.

| N. | UniProt ID (UniProt) | UniProt Name (Gene) | pI/Mw | Level µg/mL | EmPAI | Cancer |
|---|----------------|-------------------|------|-------------|-------|-------|
| 84 | P27918 PROP_HUMAN | Properdin (CFP) | 8.33/48,494 | 0.33 | 1.7 | [233] |
| 85 | P07225 PROS_HUMAN | Vitamin K-dependent protein S (PROS1) | 5.17/70,645 | 1.7 | 7.7 | [234] |
| 86 | P02753 RET4_HUMAN | Plasma retinol-binding protein 4 (PRBP) | 5.27/21,072 | 580 | 39.3 | [235–237] |
| 87 | P0DJ18 SAA1_HUMAN | Serum amyloid A-1 (SAA1) | 5.89/11,683 | 7.4 | 4.3 | [32,34,238–240] |
| 88 | P02743 SAMP_HUMAN | Serum amyloid P-component (APCS) | 6.12/23,259 | 8.7 | 39.5 | [241] |
| 89 | P04278 SHBG_HUMAN | Sex hormone-binding globulin (SHBG) | 5.83/40,468 | 0.26 | 5.8 | [242,243] |
| 90 | P05109 S10A8_HUMAN | Protein S100-A8 (S100A8) | 6.50/10,835 | 0.27 | 0.9 | [244–246] |
| 91 | P06702 S10A9_HUMAN | Protein S100-A9 (S100A9) | 5.71/13,242 | 1.9 | 2.6 | [244,247] |
| 92 | P05452 TETN_HUMAN | Tetrane (CLEC3B) | 5.80/20,139 | 58 | 31.5 | [32,248,249] |
| 93 | P05543 THBG_HUMAN | Thyroxine-binding globulin (SERPINA7) | 5.76/44,102 | 1.3 | 12.5 | [250,251] |
| 94 | P00734 THR_HUMAN | Prothrombin (F2) | 5.23/65,308 | 27 | 24.8 | [252,253] |
| 95 | P02787 TRFE_HUMAN | Serotransferrin (TF) | 6.70/75,195 | 360 | 41.8 | [25,254] |
| 96 | P02766 TTHY_HUMAN | Transthyretin (TTR) | 5.31/13,761 | 770 | 23.9 | [32,254,255] |
| 97 | P02774 VTDB_HUMAN | Vitamin D-binding protein (GC) | 5.16/51,197 | 57 | 181.4 | [32,255,256] |
| 98 | P04004 VTNC_HUMAN | Vitronectin (VTN) | 5.47/52,278 | 35 | 22.7 | [25,32,256] |
| 99 | P25311 ZA2G_HUMAN | Zinc-alpha2-glycoprotein (AZGP1) | 5.58/32,145 | 31 | 31.5 | [261–264] |

2.1. ALPHA-1-ACID GLYCOPROTEIN 1 (A1AG1_HUMAN)

The two-dimensional electrophoresis pattern of AGP-1 represents a chain of spots in the pI-range from 3 to 5 (Supplementary Figure S1). This pattern is well-represented in the SWISS-2DPAGE (pI/Mw: 4.11–4.29/43–46,000) [22]. Such a pattern is a result of heavy glycosylation (82 N-linked glycans at 6 sites), phosphorylation (2 sites), acetylation (2 sites), ubiquitylation (1 site) (https://www.uniprot.org/uniprot/P02763 accessed on 10 September 2022).

2.2. ALPHA-1-ACID GLYCOPROTEIN 2 (A1AG2_HUMAN)

The two-dimensional electrophoresis pattern of AGP-2 is very similar to AGP-1 (Supplementary Figure S1) and in SWISS-2DPAGE is overlapped with AGP-1 pattern [22]. AGP-2 can be glycosylated (99 N-linked glycans at 7 sites) and acetylated (1 site). (https://www.uniprot.org/uniprot/P19652 accessed on 10 September 2022).

2.3. ALPHA-1-ANTITRYPSIN (A1AT_HUMAN)

The two-dimensional electrophoresis pattern of Serpin A1 represents a chain of spots in the pI-range 4.5–5.1 (Supplementary Figure S1) [265] that is a result of multiple N-linked glycosylations (112 N-linked glycans at 5 sites, 5 O-linked glycans at 6 sites), phosphorylation (13 sites), and acetylation (17 sites) (https://www.phosphosite.org/ accessed on 10 September 2022) [266]. Accordingly, in SWISS-2DPAGE, 22 spots of serpin A1 are present (pI/Mw: 4.87–5.10/48–108,000) [22].
2.4. ALPHA-1B GLYCOPROTEIN (A1BG_HUMAN)

The two-dimensional electrophoresis pattern of alpha-1-B glycoprotein represents a long chain of spots in the pI-range 4–6 and Mw ~ 54,000 (Supplementary Figure S1) that is a result of heavy glycosylation (24 N-linked glycans at 4 sites, 2 O-linked glycans at 1 site) and phosphorylation (1 site) (https://glyconnect.expasy.org/browser/proteins/780 accessed on 10 September 2022). In SWISS-2DPAGE, alpha-1-B glycoprotein is represented as a chain of six spots (pI/Mw: 4.99–5.25/73–76,000) [22].

2.5. ALPHA-2-MACROGLOBULIN (A2MG_HUMAN)

The two-dimensional electrophoresis pattern of alpha-2-M represents a chain of heavy Mw spots (mostly in the pI-range 5.8–6.3) (Supplementary Figure S1). This pattern is also well-represented in the SWISS-2DPAGE https://world-2dpage.expasy.org/ accessed on 10 September 2022 [22]. Alpha-2-M has eight sites of O-GalNAc and eight sites of N-GlcNAc (https://glygen.org/protein/P01023#glycosylation accessed on 10 September 2022).

2.6. ALPHA-2-ANTIPLASMIN (A2AP_HUMAN)

The two-dimensional electrophoresis pattern of α2AP represents a chain of spots in the pI-range 4–6 with Mw ~ 50,000 (Supplementary Figure S1) that is a result of glycosylation (4 N-linked glycans at 1 site, 3 O-linked glycans at 4 sites), phosphorylation (7 sites), and ubiquitylation (2 sites) (https://glygen.org/protein/P08697#glycosylation accessed on 10 September 2022). In SWISS-2DPAGE, alpha-2-antiplasmin is represented as a chain of seven spots (pI/Mw: 4.87–5.17/66–74,000).

2.7. LEUCINE-RICH ALPHA-2-GLYCOPROTEIN (A2GL_HUMAN)

The two-dimensional electrophoresis pattern of LRG1 represents a chain of spots in the pI-range 3.5–5.0 with Mw ~ 40,000–50,000 (Supplementary Figure S1). This pattern is well-represented in the SWISS-2DPAGE https://world-2dpage.expasy.org/ accessed on 10 September 2022 and has a characteristic for multiple glycosylation profiles, where acidic spots have higher Mw [22]. LRG1 has at least six sites of glycosylation: one is O-GalNAc and five are N-GlcNAc (https://www.uniprot.org/uniprot/P02750 accessed on 10 September 2022).

2.8. ALPHA-1-ANTICHYMOTRYPSIN (AACT_HUMAN)

The two-dimensional electrophoresis pattern of ACT represents a chain of spots in the pI-range 4.0–5.0 and Mw 50–60,000 (Supplementary Figure S1). This pattern is also well-represented in the SWISS-2DPAGE, where two chains (20 spots) of both ACT forms are presented [22]. ACT has seven sites of N-GlcNAc and four sites of O-GalNAc (https://glygen.org/protein/P01011#glycosylation accessed on 10 September 2022).

2.9. ADIPONECTIN (ADIPO_HUMAN)

The two-dimensional electrophoresis pattern of adiponectin represents a chain of spots in the pI-range 5.0–5.5 and Mw 26,000 (Supplementary Figure S1). There are six sites of O-linked glycosylation and two sites of phosphorylation in adiponectin (https://glygen.org/protein/Q15848#glycosylation accessed on 10 September 2022).

2.10. AFAMIN (AFAM_HUMAN)

The two-dimensional electrophoresis pattern of adiponectin represents a chain of spots in the pI-range 5.0–5.5 and Mw 26,000 (Supplementary Figure S1). There are six sites of O-linked glycosylation and two sites of phosphorylation in adiponectin (https://glygen.org/protein/Q15848#glycosylation accessed on 10 September 2022).

2.10. AFAMIN (AFAM_HUMAN)

The two-dimensional electrophoresis pattern of adiponectin represents a chain of spots in the pI-range 5.0–5.5 and Mw 26,000 (Supplementary Figure S1). There are six sites of O-linked glycosylation and two sites of phosphorylation in adiponectin (https://glygen.org/protein/Q15848#glycosylation accessed on 10 September 2022).

2.11. ALBUMIN (ALBU_HUMAN)

The two-dimensional electrophoresis pattern of albumin represents a chain of spots in the pI-range 5.5–6.5 and Mw ~ 70,000 (Supplementary Figure S1). Its pattern is also
well-represented in the SWISS-2DPAGE [22]. Albumin can be modified by N-linked glycans at one site, 7 O-linked glycans at 11 sites, phosphorylated at multiple sites (at least 15), and acetylated (1 site) (https://glygen.org/protein/P02768#glycosylation accessed on 10 September 2022).

2.12. PROTEIN AMBP (AMBP_HUMAN)

The two-dimensional electrophoresis pattern of AMBP represents two groups of spots in the pI-range 4.0–6.5: alpha-1-microglobulin with Mw ~ 26,000 and inter-alpha-trypsin inhibitor light chain/bikunin that is assembled in a high Mw complex by a chondroitin-like glycosaminoglycan (GAG) cross-linking with Mw 120,000 (Supplementary Figure S1). In the SWISS-2DPAGE, AMBP is represented only by the chain of three alpha-1-microglobulin spots. AMBP can be glycosylated (31 N-Linked glycans at 2 sites, 7 O-Linked glycans at 3 sites), phosphorylated (3 sites), and acetylated (1 site) (https://www.phosphosite.org/ accessed on 10 September 2022).

2.13. ANGIOTENSINOGEN (ANGT_HUMAN)

The two-dimensional electrophoresis pattern of angiotensinogen represents a chain of spots in the pI-range 4.0–6.4 and Mw ~ 50,000 (Supplementary Figure S1). In the SWISS-2DPAGE, angiotensinogen is represented by one spot (pI/Mw: 5.07/58,973). It was reported that there were 20 N-linked glycans at 3 sites and 1 O-linked glycan (1 site) (https://glygen.org/protein/P01019#glycosylation accessed on 10 September 2022).

2.14. ANTITHROMBIN-III (ANT3_HUMAN)

The two-dimensional electrophoresis pattern of ATIII represents a chain of eight spots in the pI-range 4.5–6.0 and Mw ~ 50,000 (Supplementary Figure S1). In the SWISS-2DPAGE, only two spots are presented (pI/Mw: 5.20/58,973 and 5.27/58,653) for ATIII [22]. The protein can be glycosylated (24 N-linked glycans at 4 sites, 2 O-linked glycans at 1 site), phosphorylated (9 sites), and ubiquitinated (1 site) (https://www.phosphosite.org/ accessed on 10 September 2022).

2.15. APOLIPOPROTEIN A-I (APOA1_HUMAN)

The two-dimensional electrophoresis pattern of apoA-I represents a chain of spots in the pI-range 4.5–6.5 and Mw ~ 26,000 (Supplementary Figure S1). In the SWISS-2DPAGE, nine spots are presented (chain of five spots pI/Mw: 4.99–5.48/~23,000 and four spots with Mw ~ 8000–9000) [22]. The protein can be heavily phosphorylated (13 sites), acetylated (13 sites), ubiquitinated (7 sites), succinylated (3 sites), or glycosylated (2 sites) (https://www.phosphosite.org/ accessed on 10 September 2022).

2.16. APOLIPOPROTEIN A-II (APOA2_HUMAN)

The two-dimensional electrophoresis pattern of apoA-II represents a chain of spots in the pI-range 4.5–6.0 and Mw ~ 9000 (Supplementary Figure S1). In the SWISS-2DPAGE, two spots are presented (pI/Mw: 4.74/12,520 and 4.71/7250) [22]. ApoA-II can be glycosylated (3 O-linked glycans at 3 sites), phosphorylated (7 sites), acetylated (1 site), or succinylated (1 site).

2.17. APOLIPOPROTEIN A-IV (APOA4_HUMAN)

The two-dimensional electrophoresis pattern of apoA-IV represents a chain of spots in the pI-range 4.5–6.0 and Mw ~ 40,000 (Supplementary Figure S1). In the SWISS-2DPAGE, six spots are presented (pI/Mw: 5.05–5.10/~43,000 (3 spots), 5.11/21,945, and 4.87–4.97/9–10,000 (3 spots)). ApoA-IV can be glycosylated (1 O-linked glycan at 1 site), phosphorylated (7 sites), acetylated (9 site), or ubiquitinated (1 site) (https://www.phosphosite.org/ accessed on 10 September 2022).
2.18. APOLIPOPROTEIN B-100 (APOB_HUMAN)

The two-dimensional electrophoresis pattern of apo B-100 represents a long chain of spots in the pI-range 3.5–7.5 and heavy Mw > 120,000 (Supplementary Figure S1). Apo B-100 can be glycosylated (28 sites, 82 N-linked glycans at 16 sites, 1 O-linked glycan at 7 sites), phosphorylated (43 sites), acetylated (4 sites), or ubiquitinated (8 sites) (https://www.phosphosite.org/ accessed on 10 September 2022).

2.19. APOLIPOPROTEIN C-I (APOC1_HUMAN)

The two-dimensional electrophoresis pattern of apo-CI represents a chain of spots in the pI-range 7.8–8.5 and Mw ~ 6000 (Supplementary Figure S1). This protein can be acetylated (3 sites) and ubiquitinated (4 sites) (https://www.phosphosite.org/ accessed on 10 September 2022).

2.20. APOLIPOPROTEIN C-II (APOC2_HUMAN)

The two-dimensional electrophoresis pattern of apo-CII represents a chain of spots in the pI-range 4.8–5.2 and Mw ~ 8000 (Supplementary Figure S1). In the SWISS-2DPAGE, two spots for apo-CII are presented (pI/Mw: 4.51/9976 and 4.58/9248). This protein can be acetylated (5 sites), ubiquitinated (2 sites) (https://www.phosphosite.org/ accessed on 10 September 2022), and glycosylated (3 O-linked glycans at 4 sites) (https://www.glygen.org/protein/P02655 accessed on 10 September 2022).

2.21. APOLIPOPROTEIN C-III (APOC3_HUMAN)

The two-dimensional electrophoresis pattern of apoC-III represents a chain of spots in the pI-range 3.8–6.1 and Mw ~ 9000 (Supplementary Figure S1). In the SWISS-2DPAGE, only one spot for apoC-III is presented (pI/Mw: 4.63/8528). This protein can be phosphorylated (7 sites) acetylated (1 site), ubiquitinated (1 site) (https://www.phosphosite.org/ accessed on 10 September 2022), and glycosylated (4 O-linked glycans at 1 site) (https://www.glygen.org/protein/P02655 accessed on 10 September 2022).

2.22. APOLIPOPROTEIN D (APOD_HUMAN)

The two-dimensional electrophoresis pattern of apoD represents an unusual set of spots in the pI-range 3.5–6.5 and Mw from ~15,000 to ~26,000 and 80,000 (Supplementary Figure S1). In the SWISS-2DPAGE, a cluster of 12 spots for apoD is presented (pI/Mw: 4.44–4.78/27–32,000). ApoD can be heavily glycosylated (115 N-linked glycans at 2 sites, 1 O-linked glycan at 1 site) and phosphorylated (1 site) (https://www.uniprot.org/uniprotkb/P05090/entry accessed on 10 September 2022).

2.23. APOLIPOPROTEIN E (APOE_HUMAN)

The two-dimensional electrophoresis pattern of apoE represents a chain of spots in the pI-range 4.5–6.5 and Mw ~ 35,000 (Supplementary Figure S1). In the SWISS-2DPAGE, there is a chain of three spots (pI/Mw: 5.24–5.49/34–35,320). ApoE can be glycosylated (6 O-linked glycans at 6 sites), phosphorylated (9 sites), acetylated (1 site), and ubiquitinated (5 sites) (https://www.phosphosite.org/ accessed on 10 September 2022).

2.24. APOLIPOPROTEIN F (APOF_HUMAN)

The two-dimensional electrophoresis pattern of apo-F represents a set of spots in the pI-range 3.5–4.2 and Mw from ~15,000 to ~32,000 (Supplementary Figure S1). ApoF can be glycosylated (16 N-linked glycans at 3 sites, 6 O-linked glycans at 5 sites), phosphorylated (1 site), and ubiquitinated (2 sites) (https://www.phosphosite.org/ accessed on 10 September 2022).

2.25. BETA-2-GLYCOPROTEIN 1 (APOH_HUMAN)

The two-dimensional electrophoresis pattern of apo-H represents a chain of spots in the pI-range 6.2–8.4 and Mw ~ 52,000 (Supplementary Figure S1), which is much higher
than the theoretical one because of heavy glycosylation (85 N-linked annotations at 4 sites and 3 O-linked annotations at 3 sites) (https://glygen.org/protein/P02749#glycosylation accessed on 10 September 2022).

2.26. APOLIPOPROTEIN M (APOM_HUMAN)

The two-dimensional electrophoresis pattern of apoM represents a chain of spots in the pI-range 4.5–6.5 and Mw ~ 22,000 (Supplementary Figure S1). There are 13 N-linked annotations at 1 site (N135) in apoM (https://glygen.org/protein/O95445#glycosylation accessed on 10 September 2022).

2.27. Complement System

The results of several studies suggest that changes in the complement system can not only promote an antitumor response but can also influence tumor development through proliferation, survival, angiogenesis, and invasiveness [267,268]. The presence of many complement components with different functions makes the study of this system very difficult [269]. In any case, it is becoming clear that complement activation stimulates carcinogenesis and protects against immune destruction, although it has long been believed that the complement system helps the body identify and eliminate transformed cells. Moreover, the complement is activated by different mechanisms in the case of different types of cancer, and the results of activation may be different for different types of cancer or over time for the same tumor [270–272].

2.27.1. C1r (C1R_HUMAN)

The two-dimensional electrophoresis pattern represents only a chain of spots of the complement C1r subcomponent in the pI-range 4.5–6.2 and Mw ~ 80,000 (Supplementary Figure S1) that corresponds to only a complement C1r subcomponent. The cleaved heavy and light chains were not detected. There are 25 N-linked glycosylation annotations at four sites and one phosphorylation site in the complement C1r subcomponent (https://glygen.org/protein/P00736#glycosylation accessed on 10 September 2022).

2.27.2. C1S (C1S_HUMAN)

The two-dimensional electrophoresis pattern represents a chain of five spots of C1s in the pI-range from 4.0 to 4.9 and Mw ~ 80,000 (Supplementary Figure S1). The cleaved heavy and light chains were not detected. There are seven N-linked glycans at two sites (https://glygen.org/protein/P09871#glycosylation accessed on 10 September 2022).

2.27.3. COMPLEMENT C1qC (C1QC_HUMAN)

The two-dimensional electrophoresis pattern of C1q represents a long horizontal chain of spots in the pI-range 3.0–9.5 with Mw ~ 23,000 and a vertical chain of heavy complexes (Mw 23,000 and up) with pI ~ 9.0 (Supplementary Figure S1). It was reported there was only one O-linked glycosylation of C1q (https://glygen.org/protein/P02747#glycosylation accessed on 10 September 2022).

2.27.4. COMPLEMENT FACTOR I (CFAI_HUMAN)

The two-dimensional electrophoresis pattern of the complement factor I represents the chains of many spots in the pI-range 4.5–6.8 from Mw ~ 64,000 (complement factor I) to Mw ~ 30,000 (the complement factor I heavy and light chains) (Supplementary Figure S1). In the SWISS-2DPAGE, the complement factor I is represented only by one spot (pI/Mw: 5.03/37,900). There are 57 N-linked glycosylation annotations at 6 sites for the complement factor I (https://glygen.org/protein/P05156#glycosylation accessed on 10 September 2022).

2.27.5. COMPLEMENT FACTOR B (CFAB_HUMAN)

The two-dimensional electrophoresis pattern of the complement factor B represents the chains of spots in the pI-range 4.5–6.8 with Mw ~ 90,000 (Supplementary Figure S1). The
cleaved heavy and light chains were not detected. In the SWISS-2DPAGE, the complement factor B is represented by a chain of six spots (pI 5.88–6.28, Mw ~ 100,000). There are 19 N-linked glycans (4 sites), and 3 O-linked glycans (3 sites) in the complement factor B (https://glygen.org/protein/P00751#glycosylation accessed on 10 September 2022).

2.27.6. COMPLEMENT FACTOR D (CFAD_HUMAN)

The two-dimensional electrophoresis pattern of the complement factor D represents two spots (pI ~8.0, Mw 25,000) (Supplementary Figure S1). The protein can be phosphorylated (2 sites), glycosylated (2 sites), ubiquitinated (2 sites), and methylated (1 site) (https://www.phosphosite.org accessed on 10 September 2022).

2.27.7. COMPLEMENT FACTOR H (CFAH_HUMAN)

The two-dimensional electrophoresis pattern of the complement factor D represents a long chain of spots in the pI-range 5.5–7 with Mw ~ 140,000 (Supplementary Figure S1). It was reported there were 62 N-linked glycans in 9 sites in the complement factor D (https://glygen.org/protein/P08603#glycosylation accessed on 10 September 2022).

2.27.8. COMPLEMENT C2 (CO2_HUMAN)

The two-dimensional electrophoresis pattern of the complement C2 represents a chain of spots in the pI-range 6–7 with Mw ~ 80,000 (Supplementary Figure S1). It was reported there were 33 N-linked glycosylations at 9 sites and one phosphorylation (S266) of the complement C2 (https://glygen.org/protein/P06681#glycosylation accessed on 10 September 2022).

2.27.9. COMPLEMENT C3 (CO3_HUMAN)

The two-dimensional electrophoresis pattern of the complement C3 represents a cluster of spots in the pI-range 3.5–7.5 and Mw from ~30,000 to 180,000 (Supplementary Figure S1). In the SWISS-2DPAGE, there are the complement C3 beta chain (5 spots with pI 6.81–6.98, Mw ~ 71,000) and the complement C3dg fragment (a spot with pI 4.84 and Mw 40,915). There are 50 N-linked glycans at 4 sites, 2 O-linked glycans at 2 sites, and 12 phosphorylation sites (https://glygen.org/protein/P01024#glycosylation accessed on 10 September 2022).

2.27.10. COMPLEMENT C4-A (CO4A_HUMAN)

The two-dimensional electrophoresis pattern of the complement C4-A represents a wide cluster of spots in the pI-range 3.0–10.0 and Mw from ~25,000 to 190,000 (Supplementary Figure S1). There are 35 N-linked glycans (4 sites), 6 O-linked glycans (4 sites), and 3 phosphoserine sites (https://glygen.org/protein/P0C0L4#glycosylation accessed on 10 September 2022).

2.27.11. COMPLEMENT C4-B (C4B) (CO4B_HUMAN)

The two-dimensional electrophoresis pattern of the complement C4-B represents a wide cluster of spots in the pI-range 3.0–10.0 and Mw from ~35,000 to 19,0000 (Supplementary Figure S1). In the SWISS-2DPAGE, only a complement C4 gamma chain (2 spots with pI/Mw: 6.41/31,942 and 6.54/31,735) was detected. It was reported there were 34 N-linked glycans (4 sites) and 1 O-linked glycan (1 site) in the complement C4-B (https://glygen.org/protein/P0C0L5#glycosylation accessed on 10 September 2022).

2.27.12. COMPLEMENT C5 (CO5_HUMAN)

The two-dimensional electrophoresis pattern of the complement C4-B represents a wide cluster of spots in the pI-range 5.0–6.8 and Mw ~ 70,000–190,000 (Supplementary Figure S1). It was reported there were eight N-linked glycans at three sites (https://glygen.org/protein/P01031#glycosylation accessed on 10 September 2022).
2.27.13. COMPLEMENT C6 (CO6_HUMAN)

The two-dimensional electrophoresis pattern of the complement C6 represents a chain of spots in the pI-range 4.0–6.5 and Mw ~ 100,000 (Supplementary Figure S1). It was reported there were 6 C-linked annotations at 6 sites, 12 N-linked annotations at 4 sites, 2 O-linked annotations at 2 sites (https://glygen.org/protein/P13671#glycosylation accessed on 10 September 2022), and 5 sites of phosphorylation (https://www.phosphosite.org/ accessed on 10 September 2022).

2.27.14. COMPLEMENT C7 (CO7_HUMAN)

The two-dimensional electrophoresis pattern of the complement C7 represents a chain of spots in the pI-range 4.5–6.5 and Mw ~ 100,000 (Supplementary Figure S1). It was reported there were three N-linked glycans at two sites and two O-linked glycans at one site (https://glygen.org/protein/P10643#glycosylation accessed on 10 September 2022).

2.27.15. COMPLEMENT C9 (CO9_HUMAN)

The two-dimensional electrophoresis pattern of the complement C9 represents a chain of spots in the pI-range 4.5–5.5 and Mw ~ 60,000 (Supplementary Figure S1). The protein can be glycosylated (10 N-linked glycans at 2 sites, 4 O-linked glycans at 5 sites), phosphorylated (10 sites), acetylated (1 site), and ubiquitinated (3 sites) (https://www.phosphosite.org/ accessed on 10 September 2022).

2.28. CARBONIC ANHYDRASE I (CAH1_HUMAN)

The two-dimensional electrophoresis pattern of CAB represents a chain of spots in the pI-range 5–7 and Mw ~ 28,000 (Supplementary Figure S1). It was reported there was glycosylation (2 O-linked at 2 sites) (https://glygen.org/protein/P00915#glycosylation accessed on 10 September 2022), phosphorylation (11 sites), acetylation (5 sites), and ubiquitylation (2 sites) (https://www.phosphosite.org/ accessed on 10 September 2022).

2.29. CORTICOSTEROID-BINDING GLOBULIN (CBG_HUMAN)

The two-dimensional electrophoresis pattern of CBG represents a chain of spots in the pI-range 3.7–5.1 and Mw ~ 50,000 (Supplementary Figure S1). It was reported there were 48 N-linked glycosylations at 6 sites and 2 O-linked glycosylations at 1 site (https://glygen.org/protein/P08185#glycosylation accessed on 10 September 2022).

2.30. CARBOXYPEPTIDASE N CATALYTIC CHAIN (CBPN_HUMAN)

The two-dimensional electrophoresis pattern of CBPN represents a chain of spots in the pI-range 4.5–7 and Mw ~ 50,000 (Supplementary Figure S1). It was reported there were 32 N-linked glycans at 5 sites and 2 O-linked glycans at 1 site (https://glygen.org/protein/P08185#glycosylation accessed on 10 September 2022).

2.31. MONOCYTE DIFFERENTIATION ANTIGEN CD14 (CD14_HUMAN)

The two-dimensional electrophoresis pattern of CD14 represents a chain of spots in the pI-range 4.5–5.8 and Mw ~ 40,000 (Supplementary Figure S1). It was reported there were 26 N-linked glycans at 2 sites and 4 O-linked glycans at 3 sites (https://glygen.org/protein/P08571#glycosylation accessed on 10 September 2022).

2.32. CERULOPLASMIN (CERU_HUMAN)

The two-dimensional electrophoresis pattern of ceruloplasmin represents a chain of spots in the pI-range 4.0–6.2 and Mw ~ 120,000 (Supplementary Figure S1). In the SWISS-2DPAGE, 3 chains of 27 spots with pI 4.96–5.24 and Mw ~ 120–16,000 are present. There are 237 N-linked annotations at 8 sites, 10 O-linked annotations at 7 sites of glycosylation, and 3 sites of phosphorylation for ceruloplasmin (https://glygen.org/protein/P00450#glycosylation accessed on 10 September 2022).
2.33. CHOLINESTERASE (CHLE_HUMAN)

The two-dimensional electrophoresis pattern of cholinesterase represents a chain of five spots in the pI-range 4.5–5.2 and Mw ~ 65,000 (Supplementary Figure S1). There are 34 N-linked annotations at 12 sites, one O-linked annotation for glycosylation, and phosphorylation at S226 for cholinesterase (https://glygen.org/protein/P06276#glycosylation accessed on 10 September 2022).

2.34. CLUSTERIN (CLUS_HUMAN)

The two-dimensional electrophoresis pattern of ceruloplasmin represents a chain of 18 spots in the pI-range 4.5–6.5 and Mw ~ 35,000 (Supplementary Figure S1). In the SWISS-2DPAGE, 17 spots with pI 4.73–5.07 and Mw ~ 35–39,000 are shown. Clusterin is heavily glycosylated (149 N-linked glycans at 6 sites, O-linked glycan at 1 site) and phosphorylated (4 sites) (https://glygen.org/protein/P10909#glycosylation accessed on 10 September 2022).

2.35. BETA-ALA-HIS DIPEPTIDASE (CNDP1_HUMAN)

The two-dimensional electrophoresis pattern of beta-Ala-His dipeptidase represents two spots around pI 5.0 and Mw ~ 54,000 (Supplementary Figure S1). It was reported there were 18 N-linked glycans at 1 site, 1 O-linked glycan at 2 sites, and phosphorylation at S219 (https://glygen.org/protein/Q96KN2#glycosylation accessed on 10 September 2022).

2.36. CARBOXYPEPTIDASE N SUBUNIT 2 (CPN2_HUMAN)

The two-dimensional electrophoresis pattern of carboxypeptidase N subunit 2 represents nine spots with pI 3.5–5.5 and Mw ~ 65,000 (Supplementary Figure S1). It is known there were 10 N-linked glycans at 3 sites in carboxypeptidase N subunit 2 (https://www.glygen.org/protein/P22792 accessed on 10 September 2022).

2.37. C-REACTIVE PROTEIN (CRP_HUMAN)

The two-dimensional electrophoresis pattern of CRP represents a single spot (pI/Mw: 5.2/24,000) (Supplementary Figure S1). In the SWISS-2DPAGE, a similar situation exists—a single spot (pI/Mw: 5.12/23,760). Thus far, it was reported there was only one PTM (a pyroglutamic acid, Q19) for CRP (https://www.uniprot.org/uniprotkb/P02741/entry accessed on 10 September 2022).

2.38. EXTRACELLULAR MATRIX PROTEIN I (ECM1_HUMAN)

The two-dimensional electrophoresis pattern of ECM1 represents a spot (pI/Mw: 6.0/60,000) (Supplementary Figure S1). It was reported there were 21 N-linked glycans at 4 sites, and 3 O-linked glycans at 6 sites (https://www.glygen.org/protein/Q16610 accessed on 10 September 2022).

2.39. FIBULIN-1 (FBLN1_HUMAN)

The two-dimensional electrophoresis pattern of FIBL-1 represents a chain of four spots (pI/Mw: 4.5–5.2/75,000) (Supplementary Figure S1). It was reported there were 10 N-linked glycans at two sites, one O-linked glycan, and one phosphorylation at S147 (https://www.glygen.org/protein/P23142 accessed on 10 September 2022).

2.40. FICOLIN-3 (FCN3_HUMAN)

The two-dimensional electrophoresis-pattern of ficolin-3 represents a chain of five spots (pI/Mw: 5.8–6.5/30,000) (Supplementary Figure S1). It was reported there were five N-linked annotation(s) at one site (https://www.glygen.org/protein/O75636 accessed on 10 September 2022).
2.41. ALPHA-2-HS-GLYCOPROTEIN (FETUA_HUMAN)

The two-dimensional electrophoresis-pattern of fetuin-A represents a set of proteoforms (pI/Mw: 3.7–6.3/~40,000-up) (Supplementary Figure S1). In the SWISS-2DPAGE, 15 spots (pI/Mw: 4.56–4.77/52–58,000) are shown. The protein is heavily glycosylated (126 N-linked annotations at 2 sites, 43 O-linked annotations at 14 sites) and phosphorylated (https://www.glygen.org/protein/P02765 accessed on 10 September 2022).

2.42. FETUIN-B (FETUB_HUMAN)

The two-dimensional electrophoresis pattern of fetuin-B represents a chain of proteoforms (pI/Mw: 5.0–6.3/50,000-up) (Supplementary Figure S1). The protein is heavily glycosylated (26 N-linked annotations at 3 sites, 8 O-linked annotation(s) at 6 sites) and phosphorylated (https://www.glygen.org/protein/Q9UGM5 accessed on 10 September 2022).

2.43. FIBRINOGEN ALPHA CHAIN (FIBA_HUMAN)

The two-dimensional electrophoresis pattern of FBA represents several sets of chains with pI 5.0–7.5 (Mw ~ 30–35,000, Mw ~ 64–83,000, Mw ~ 110,000 and up) (Supplementary Figure S1). In the SWISS-2DPAGE, a double chain of 19 spots (pI/Mw: 6.65–7.78/63–67,000) is presented [22]. The protein can be heavily glycosylated (12 N-linked annotations at 3 sites, 43 O-linked annotations at 34 sites) and phosphorylated (https://www.glygen.org/protein/P02671 accessed on 10 September 2022).

2.44. FIBRINOGEN BETA CHAIN (FIBB_HUMAN)

The two-dimensional electrophoresis-pattern of FBB represents a chain of spots (pI/Mw: 5.5–8.5/~52,000) (Supplementary Figure S1). In the SWISS-2DPAGE, a chain of four spots (pI/Mw: 6.1–6.55/55–56,000) is presented [22]. The protein can be glycosylated (52 N-linked annotations at 4 sites and 5 O-linked annotations at 3 sites) (https://www.glygen.org/protein/P02675 accessed on 10 September 2022).

2.45. FIBRINOGEN GAMMA CHAIN (FIBG_HUMAN)

The two-dimensional electrophoresis-pattern of FGG represents a chain of spots with pI 4.5–7 (Mw ~ 50,000) (Supplementary Figure S1). In the SWISS-2DPAGE, 3 chains of 13 spots (pI/Mw: 5.07–5.65/44–51,000) are presented [22]. The protein is glycosylated (39 N-linked annotations at 4 sites, 1 O-linked annotation at 1 site) and phosphorylated at S68 (https://www.glygen.org/protein/P02679 accessed on 10 September 2022).

2.46. FIBRONECTIN (FINC_HUMAN)

The two-dimensional electrophoresis pattern of fibronectin represents a chain of spots with pI 4.5–6.7 (Mw ~ 112,000 up) (Supplementary Figure S1). The protein is heavily glycosylated (265 N-linked annotations at 13 sites, 37 O-linked annotations at 25 sites) and phosphorylated (https://www.glygen.org/protein/P02751 accessed on 10 September 2022).

2.47. PLASMA GELSOLIN (GELS_HUMAN)

The two-dimensional electrophoresis pattern of gelsolin represents a chain of spots with pI 4.5–6.5 (Mw ~ 83,000) (Supplementary Figure S1). The protein can be heavily phosphorylated (25 sites), acetylated (12 sites), and ubiquitinated (10 sites) (https://www.phosphosite.org accessed on 10 September 2022).

2.48. GLUTATHION PEROXIDASE 3 (GPX3_HUMAN)

The two-dimensional electrophoresis pattern of this protein represents a chain of spots with pI 4.9–6.9 (Mw ~ 25,000) (Supplementary Figure S1). It is phosphorylated (4 sites) and acetylated (3 sites) (https://www.phosphosite.org/ accessed on 10 September 2022).
2.49. **HEMOGLOBIN SUBUNIT ALPHA (HBA_HUMAN)**

The two-dimensional electrophoresis pattern of this protein represents a chain of spots with pI 7.5–9 (Mw ~ 15,000) (Supplementary Figure S1). In the SWISS-2DPAGE, two spots (pI/Mw: 9.2/11,000, 8.9/11,000) are presented. The protein is glycosylated (3 O-linked annotations at 3 sites), glycated (6 sites) (https://www.glygen.org/protein/P69905 accessed on 10 September 2022), phosphorylated (17 sites), acetylated (4 sites), and ubiquitinated (8 sites) (https://www.phosphosite.org/ accessed on 10 September 2022).

2.50. **HEMOGLOBIN SUBUNIT BETA (HBB_HUMAN)**

The two-dimensional electrophoresis-pattern of this protein represents a chain of spots with pI 6.5–6.9 (Mw ~ 15,000) (Supplementary Figure S1). In the SWISS-2DPAGE, two spots (pI/Mw: 7/15,000, 6.9/15,000) are presented. The protein is glycosylated (4 O-linked annotations at 4 sites), glycated (6 sites), and phosphorylated (14 sites) (https://www.glygen.org/protein/P68871 accessed on 10 September 2022).

2.51. **HEMOPEXIN (HEMO_HUMAN)**

The two-dimensional electrophoresis pattern of this protein represents a chain of spots with pI 5–6.9 (Mw ~ 50,000) (Supplementary Figure S1). In the SWISS-2DPAGE, chains of five spots (pI 5.25–5.59/Mw ~ 72–77,000) and two spots (4.48/19,274, 4.56/18,289) are presented. The protein is glycosylated (184 N-linked annotations at 6 sites, 21 O-linked annotations at 6 sites) (https://www.glygen.org/protein/P02790 accessed on 10 September 2022).

2.52. **HEPARIN COFACTOR 2 (HEP2_HUMAN)**

The two-dimensional electrophoresis-pattern of this protein represents a chain of spots with pI 4.9–6.5 (Mw ~ 55,000) (Supplementary Figure S1). The protein is glycosylated (39 N-linked annotations at 3 sites, 13 O-linked annotations at 9 sites) and phosphorylated at S37 (https://www.glygen.org/protein/P05546 accessed on 10 September 2022).

2.53. **HAPTOGLOBIN (HPT_HUMAN)**

The two-dimensional electrophoresis pattern of Hp represents ~16 spots of beta chains with pI 4.8–6.0 (Mw ~ 40,000) and 3 spots of alpha 2 chain (Figure 2). In the SWISS-2DPAGE, a chain of 19 spots (pI 4.88–5.86/Mw ~ 40,000, beta chain), 3 spots (pI 5.68–6.37/Mw ~ 17,000, alpha 2 chain), and 2 spots (pI 5.13–5.37/Mw ~ 12,000, alpha 1 chain) are presented. Hp is heavily glycosylated (351 N-linked annotations at 4 sites, 1 O-linked annotations at 1 site) (https://www.glygen.org/protein/P00738 accessed on 10 September 2022).

2.54. **HAPTOGLOBIN-RELATED PROTEIN (HPTR_HUMAN)**

The two-dimensional electrophoresis pattern of this protein represents a chain of spots with pI 4.6–6.5 (Mw ~ 40,000) (Supplementary Figure S1). The protein is N-linked glycosylated (5 sites), acetylated (1 site), and ubiquitinated (2 sites) (https://www.phosphosite.org/ accessed on 10 September 2022).

2.55. **HISTIDINE-RICH GLYCOPROTEIN (HRG_HUMAN)**

The two-dimensional electrophoresis-pattern of this protein represents a chain of spots with pI 4.5–7.8 (Mw ~ 64,000) and spots around pI/Mw: 5.5/53,000 (Supplementary Figure S1). In the SWISS-2DPAGE, only a single spot (pI/Mw: 5.3/53,000) is present. The protein is glycosylated (44 N-linked glycans at 4 sites, 4 O-linked glycans at 3 sites) (https://www.glygen.org/protein/P04196 accessed on 10 September 2022).
Figure 2. Two-dimensional electrophoresis patterns of haptoglobin alpha and beta chains. (a) A sectional analysis of alpha and beta chains. The stained gel was divided into the sections with the predetermined coordinates. Then each section was treated and analyzed by LC ESI-MS/MS (see Materials and Methods, Section 4.2, 2DE). According to the abundance (emPAI) of Hpt in each section, the graph was plotted. (b) A semi-virtual 2DE of alpha and beta chains (see Materials and Methods, Section 4.2, 2DE). According to the emPAI of alpha chain (theoretical Mw: 15,946) or beta chain (theoretical Mw: 27,265) in the sections, the graph was plotted. The ball size is proportional to emPAI in each section. (c) Two-dimensional electrophoresis–Western of beta chain. (d) Two-dimensional electrophoresis–Western of alpha2 chain.

2.56. PLASMA PROTEASE C1 INHIBITOR (IC1_HUMAN)

The two-dimensional electrophoresis pattern of this protein represents a long chain of spots with pI 3.2–5.2 (Mw ~ 64,000). The protein is heavily glycosylated (107 N-linked annotations at 8 sites, 33 O-linked annotations at 21 sites) (https://www.glygen.org/protein/P05155 accessed on 10 September 2022).

2.57. INTER-ALPHA-TRYPSIN INHIBITOR HEAVY CHAINS (ITIH1, ITIH2, ITIH3, ITIH4, ITIH5)

In our experiments, 2DE patterns of these proteins are presented by the chains of the precursor proteoforms and the mature ITIH1 (Supplementary Figure S1). The proteins are heavily glycosylated, phosphorylated, acetylated, and ubiquitinated (https://www.glygen.org/protein/P05155 accessed on 10 September 2022).

2.58. KALLISTATIN (KAIN_HUMAN)

In our experiments, the 2DE pattern of this protein is presented as a cluster of proteoforms around pI/Mw: 6–7/40–120,000 (Supplementary Figure S1). The protein is glycosylated (31 N-linked annotations at 4 sites) and phosphorylated (https://www.glygen.org/...
2.59. **KININOGEN 1 (KNG1_HUMAN)**

The two-dimensional electrophoresis pattern of this protein represents multiple spots (pI 3.5–8.5, Mw ~ 35–64,000) (Supplementary Figure S1). In the SWISS-2DPAGE, only a single spot (pI/Mw: 6.48/7490) is present. The protein can be heavily glycosylated (159 N-linked annotations at 6 sites, 65 O-linked annotations at 26 sites) (https://www.glygen.org/protein/P01042 accessed on 10 September 2022), phosphorylated, acetylated, and ubiquitinated (https://www.phosphosite.org/ accessed on 10 September 2022).

2.60. **PHOSPHATIDYLCHOLINE-STEROL ACYLTRANSFERASE (LCAT_HUMAN)**

The two-dimensional electrophoresis pattern of this protein represents three spots (pI 4.0–4.8, Mw ~ 50,000) (Supplementary Figure S1). The protein is glycosylated (22 N-linked annotations at 5 sites, 3 O-linked annotations at 3 sites) (https://www.glygen.org/protein/P04180 accessed on 10 September 2022), phosphorylated, and ubiquitinated (https://www.phosphosite.org/ accessed on 10 September 2022).

2.61. **LUMICAN (LUM_HUMAN)**

The two-dimensional electrophoresis pattern of this protein represents chains of spots (pI 4.5–6.5, Mw ~ 52–83,000) (Supplementary Figure S1). The protein has multiple PTMs: (97 N-linked glycans at 4 sites, 2 O-linked glycans at 3 sites, phosphorylation (11 sites), and acetylation (8 sites) (https://www.uniprot.org/uniprotkb/P51884/entry accessed on 10 September 2022).

2.62. **MANNOSE-BINDING PROTEIN C (MBL2_HUMAN)**

The two-dimensional electrophoresis pattern of this protein represents just a single spot (pI/Mw: 5.3/26,000) (Supplementary Figure S1).

2.63. **PIGMENT EPITHELIUM-DERIVED FACTOR (PEDF_HUMAN)**

The two-dimensional electrophoresis-pattern of this protein represents a chain of spots (pI 4.5–6.5, Mw ~ 40–52,000) (Supplementary Figure S1). The protein is glycosylated (10 N-linked glycans at 1 site, 2 O-linked glycans at 7 sites), phosphorylated (10 sites), acetylated, and methylated (https://www.uniprot.org/uniprotkb/P36955/entry accessed on 10 September 2022).

2.64. **N-ACETYLMURAMOYL-L-ALANINE AMIDASE (PGRP2_HUMAN)**

The two-dimensional electrophoresis pattern of this protein represents a chain of spots (pI 5.5–6.8, Mw ~ 52–64,000) (Supplementary Figure S1). The protein is glycosylated (12 N-linked glycans at 3 sites, 4 O-linked glycans at 7 sites) and phosphorylated (4 sites) (https://www.uniprot.org/uniprotkb/Q96PD5/entry accessed on 10 September 2022).

2.65. **PHOSPHATIDYLINOSITOL-GLYCAN-SPECIFIC PHOSPHOLIPASE D (PHLD_HUMAN)**

The two-dimensional electrophoresis pattern of this protein represents a chain of spots (pI 4.2–5.6, Mw ~ 83–116,000) (Supplementary Figure S1). The protein is glycosylated (10 sites, 22 N-linked glycans at 4 sites), phosphorylated (5 sites), and acetylated (https://www.phosphosite.org/ accessed on 10 September 2022).

2.66. **PLASMINOGEN (PLMN_HUMAN)**

The two-dimensional electrophoresis pattern of this protein represents two chains of multiple spots (pI 3.3–4.1, Mw ~ 83–116,000) and (pI 6.7–8.5, Mw ~ 83–116,000) (Supplementary Figure S1). In the SWISS-2DPAGE, a single chain (7 spots) is present (pI 6.32–6.49, Mw ~ 112–116,000). The protein is glycosylated (54 N-linked glycans at 4
sites, 12 O-linked glycans at 12 sites) and phosphorylated (15 sites) (https://www.uniprot.org/uniprotkb/P00747/entry accessed on 10 September 2022).

2.67. PARAOXONASE (PON1_HUMAN)

The two-dimensional electrophoresis pattern of this protein represents a cluster of spots (pI 4.0–5.5, Mw ~ 35–52,000) (Supplementary Figure S1). In the SWISS-2DPAGE, two spots are presented (pI/Mw: 4.84/45,937 and 4.93/43,391). The protein is glycosylated (30 N-linked glycans at 3 sites), phosphorylated (3 sites), and acetylated (1 site) (https://www.uniprot.org/uniprotkb/P27169/entry accessed on 10 September 2022).

2.68. PROPERDIN (PROP_HUMAN)

The two-dimensional electrophoresis pattern of this protein represents two spots (pI/Mw: 8.5/52,000 and 8.7/52,000) (Supplementary Figure S1). The protein is glycosylated (15 C-linked annotations at 15 sites, 2 N-linked annotations at 1 site, 4 O-linked annotations at 4 sites).

2.69. VITAMIN K-DEPENDENT PROTEIN S (PROS_HUMAN)

The two-dimensional electrophoresis pattern of this protein represents a chain of spots (pI 3.5–4.5, Mw ~ 64–83,000) (Supplementary Figure S1). The protein is glycosylated (5 N-linked annotations at 3 sites, 4 O-linked annotations at 4 sites) and phosphorylated (8 sites) (https://www.uniprot.org/uniprotkb/P07225/entry accessed on 10 September 2022).

2.70. PLASMA RETINOL-BINDING PROTEIN (RET4_HUMAN)

The two-dimensional electrophoresis pattern of this protein represents a cluster of spots (pI/Mw: ~5.0–6.0, Mw ~ 18–26,000) (Supplementary Figure S1). In the SWISS-2DPAGE, three spots are presented (pI ~ 5.0, Mw ~ 20,000). The protein can be phosphorylated and methylated (https://www.phosphosite.org/ accessed on 10 September 2022).

2.71. SERUM AMYLOID A (SAA1_HUMAN)

The two-dimensional electrophoresis pattern of this protein represents two spots (pI/Mw: ~5.6/12,000 and ~5.8/12,000) (Supplementary Figure S1). This protein is phosphorylated (5 sites) (https://www.phosphosite.org/ accessed on 10 September 2022).

2.72. SERUM AMYLOID P (SAMP_HUMAN)

The two-dimensional electrophoresis pattern of this protein represents a cluster of spots (pI/Mw: ~4.5–6.1/21–35,000) (Supplementary Figure S1). This protein is phosphorylated (7 sites), acetylated (3 sites), ubiquitinated (2 sites) (https://www.phosphosite.org/ accessed on 10 September 2022), and glycosylated (14 N-linked glycans at 1 site, 1 O-linked glycan) (https://www.glygen.org/protein/P02743 accessed on 10 September 2022).

2.73. SEX HORMONE-BINDING GLOBULIN (SHBG_HUMAN)

The two-dimensional electrophoresis pattern of this protein represents a chain of spots (pI/Mw: ~5.0–6.0/35–52,000) (Supplementary Figure S1). This protein is phosphorylated (4 sites) (https://www.phosphosite.org/ accessed on 10 September 2022) and glycosylated (12 N-linked glycans at 3 sites, 6 O-linked glycans at 1 site).

2.74. S100A8 (CALPOTECTIN) (S10A8_HUMAN)

The two-dimensional electrophoresis pattern of this protein represents one spot (pI/Mw: ~6.8/10,000) (Supplementary Figure S1). However, this protein can be heavily phosphorylated (9 sites), acetylated (https://www.phosphosite.org/ accessed on 10 September 2022), and glycosylated (1 O-linked glycan) (https://www.uniprot.org/ accessed on 10 September 2022).
2.75. **S100A9 (CALPOTECTIN) (S10A9_HUMAN)**

The two-dimensional electrophoresis pattern of S100-A9 represents one spot (pI/Mw: \(\sim 6.0/10,000\)) (Supplementary Figure S1). This protein can be phosphorylated (5 sites), acetylated (3 sites), methylated (https://www.phosphosite.org/ accessed on 10 September 2022), and glycosylated (1 O-linked glycan) (https://www.uniprot.org/ accessed on 10 September 2022).

2.76. **TETRANECTIN (TETN_HUMAN)**

The two-dimensional electrophoresis pattern of this protein represents a chain of spots (pI/Mw: \(\sim 5.5/21–26,000\)) (Supplementary Figure S1). This protein can be glycosylated (1 O-linked annotation(s) at 1 site) (https://www.uniprot.org/uniprotkb/P05452/entry accessed on 10 September 2022).

2.77. **THYROXINE-BINDING GLOBULIN (THBG_HUMAN)**

The two-dimensional electrophoresis pattern of this protein represents a chain of spots (pI/Mw: \(\sim 5.5/52–64,000\)) (Supplementary Figure S1). This protein can be glycosylated (17 N-linked glycans at 3 sites, 1 O-linked glycan) and phosphorylated (https://www.phosphosite.org/ accessed on 10 September 2022).

2.78. **PROTHROMBIN (THRB_HUMAN)**

The two-dimensional electrophoresis pattern of this protein represents a chain of spots (pI/Mw: 5–6.5/64–83,000) (Supplementary Figure S1). In the SWISS-2DPAGE, there is a chain of five spots (pI/Mw: 4.95–5.05/80,000). This protein can be glycosylated (2 N-linked glycans at 5 sites, 1 O-linked glycan at 6 sites), phosphorylated (9 sites), acetylated (1 site), and ubiquitinated (4 sites) (https://www.uniprot.org/uniprotkb/P00734/entry accessed on 10 September 2022).

2.79. **SEROTRANSFERRIN (TRFE_HUMAN)**

The two-dimensional electrophoresis pattern of this protein represents a cluster of spots (pI/Mw: 4.5–5.7/64–83,000) (Supplementary Figure S1). In the SWISS-2DPAGE, there are 22 spots (pI/Mw: 6.14–6.64/76–87,000) for serotransferrin. This protein can be glycosylated (145 N-linked glycans at 6 sites, 6 O-linked glycans at 2 sites), phosphorylated (21 sites), acetylated (10 sites), and ubiquitinated (7 sites) (https://www.phosphosite.org/ accessed on 10 September 2022).

2.80. **TRANSTHYRETIN (TTHY_HUMAN)**

The two-dimensional electrophoresis pattern of this protein represents a chain of spots (pI/Mw: \(\sim 5.7–7.0/64–83,000\)) (Supplementary Figure S1). In the SWISS-2DPAGE, there are 3 chains of 22 spots (pI/Mw: 5.02–5.52/13,800), and a spot (pI/Mw: 5.52/35,391) for transthyretin. This protein can be glycosylated (1 N-linked annotation), phosphorylated (6 sites), acetylated (2 sites), or ubiquitinated (4 sites) (https://www.phosphosite.org/ accessed on 10 September 2022).

2.81. **VITAMIN D-BINDING PROTEIN (VTDB_HUMAN)**

The two-dimensional electrophoresis pattern of this protein represents a cluster of spots (pI/Mw: \(\sim 4.5–5.7/40–52,000\)) (Supplementary Figure S1). In the SWISS-2DPAGE, there are two spots (pI/Mw: 5.16/53,772 and 5.24/53,918) for vitamin D-binding protein. This protein can be glycosylated (1 N-Linked glycan at 1 site, 1 O-Linked glycan), phosphorylated (12 sites), acetylated (1 site), or ubiquitinated (1 site) (https://www.phosphosite.org/ accessed on 10 September 2022).

2.82. **VITRONECTIN (VTNC_HUMAN)**

The two-dimensional electrophoresis pattern of this protein represents a cluster of spots (pI/Mw: 3.7–6.6/52–116,000) (Supplementary Figure S1). In the SWISS-2DPAGE,
there is only one spot (pI/Mw: 4.58/9248) for vitronectin. VN can be glycosylated (1 N-linked annotation), phosphorylated (20 sites), acetylated (1 site), and ubiquitinated (1 site) (https://www.phosphosite.org/ accessed on 10 September 2022).

2.83. ZINC-ALPHA-2-GLYCOPROTEIN (ZA2G_HUMAN)

The two-dimensional electrophoresis pattern of this protein represents a cluster of spots (pI/Mw: 4.2–5.0/35–40,000) (Supplementary Figure S1). In the SWISS-2DPAGE, there is a chain of four spots (pI/Mw: 4.8–4.97/40–42,000) for zinc-alpha-2-glycoprotein. This protein can be glycosylated (108 N-Linked glycans at 3 sites, 1 O-Linked glycan at 1 site), phosphorylated (1 site), and ubiquitinated (5 sites) (https://www.phosphosite.org/ accessed on 10 September 2022).

3. Discussion

Tumorigenesis leads to multiple variations in the human plasma proteome that can be dynamic and alterable during the progress of the disease. Practically all major, so-called “classical”, plasma proteins change abundances or PTMs. The majority of these proteins are secreted by the liver, so it could be anticipated to see these changes only in the case of liver cancer. However, they can be observed with other tumors as well as cancer induces disturbances in the blood homeostasis that is supported by “classical plasma proteins”. It follows that it is possible to search the specific/unspecific ways of tumor prediction not only through the detection of products of the tumor but also by analyzing the changes in “classic plasma proteins”. It is relevant to mention that plasma analysis by a very different approach, differential scanning calorimetry (DSC), can give us a hint. Typically, DSC is used to determine the partial heat capacity of macromolecules as a function of temperature, from which their structural stability during thermal denaturation can be assessed. The method is very sensitive and allows precise determination of thermally-induced conformational transitions of proteins present in plasma. There are already quite a few publications showing that DSC can be used to distinguish between normal and cancerous plasma samples [273,274]. Moreover, the data obtained by this method can be reproduced using major plasma proteins.

It follows that there is a possibility of building test systems based on these major (“classical”) proteins. What is important is that many examples of such systems have been introduced already. For example, the relationship between inflammation and clinical outcome is described using the Modified Glasgow Prognostic Scale (mGPS), which includes levels of C-reactive protein (CRP) and albumin [275]. The combination of elevated CRP (>10 mg/L) and decreased albumin (<35 g/L) corresponds to higher mGPS, which correlates with systemic inflammation and poor outcome of cancer therapy [276]. The OVA1 test uses the other major plasma proteins. OVA1 is an FDA-approved blood test that measures the levels of five proteins (CA125, transferrin, transthyretin, apolipoprotein A1, and beta-2 microglobulin) to detect ovarian cancer risk in women. Here, a sophisticated mathematical formula (multivariate index assay) is used to evaluate and combine the levels of these proteins in plasma, producing an ovarian cancer risk score. Using this approach, OVA1 can detect early-stage ovarian cancer with 98% specificity. The OVERA (second-generation or OVA2) assesses a woman’s malignancy risk using combined results from the following five proteins: apolipoprotein A1, human epididymis protein 4 (HE4), CA-125 II, follicle-stimulating hormone (FSH), and transferrin (Vermillion Inc. OVA1 Products. Updated 2020. Available at: https://vermillion.com/ova-products accessed on 10 September 2022).

The observation of enhanced levels of clusterin, ITIH4, antithrombin-III, and C1RL in sera of endometrial cancer patients allowed a mathematical model to be built to detect cancer samples [29]. Accordingly, by the selection of the appropriate panels (proteomics signatures) of the plasma oncomarkers, it is possible to detect/monitor different types of cancers. The main point is to select the correct set of oncomarkers and develop an algorithm that will take into account all possible changes in these oncomarkers (level, PTMs etc.) that are related to cancer. This selection should be meticulously performed based on oncomarker
behavior in plasma, not in tissue. We performed a search for publications with information (level, PTMs) about “classical” plasma proteins in the case of malignant processes in the human body (Table 1). As levels of some oncomarkers behave differently in different cancers (rise or fall), the test could specifically detect the type of cancer. Apolipoproteins are a good example here. SAA1 and CRP are APPs that are routinely measured in the clinic. The level of apoA-1 is reduced in many cancers but increased in some [80]. The decreased level of apoA-I in plasma is observed in the case of de novo myelodysplastic syndromes [83], NSCLC [84], nasopharyngeal carcinoma (NPC) [85], esophageal squamous cell carcinoma [86], and BC [75], but it is increased in SCLC, HCC, and bladder cancer [80].

Another aspect that should be considered is the appearance of proteoforms produced by genetic polymorphisms, alternative splicing, PTMs, etc. These events change the charge (pI) and the weight (Mw) of the protein. Because of that, the experimental pI/Mw of the proteins can be different from the theoretical ones. This leads to the production of sets of proteoforms that in our case are detected as 2DE patterns. There is a belief that some 2DE patterns can be different between norm and cancer and could be used as specific biomarkers. Thus far, there are not many such examples, but progress in proteomics methods should improve the situation [277,278]. Proteomics is generating and analyzing a large volume of data and these data exactly fit the situation with multiple variations in plasma proteomes during cancer development and progression. Here, high-throughput, quantitative mass spectrometry is the best choice. There is already a good example of the possibility of using it in the clinic [14]. Geyer et al. introduced a rapid and robust “plasma proteome profiling” LC-MS/MS pipeline. Their single-run shotgun proteomics workflow enables quantitative analysis of hundreds of plasma proteins from just 1 µL of plasma [14].

Our aim is to build a comprehensive proteoform database containing norm and cancer samples http://2de-pattern.pnpi.nrcki.ru/ accessed on 10 September 2022 [30]. Glioblastoma and hepatocellular carcinoma are the cancers in our study so far. The database contains only the cellular samples, but we are in the process of incorporating tissue and plasma samples.

4. Materials and Methods

4.1. Plasma

The pooled human plasma was from healthy male donors (age 20–47 years) [278,279]. Depletion of serum albumin and immunoglobulins IgG was carried out according to Agilent Multiple Affinity Removal System (MARS) protocol (“Agilent Technologies”, Santa Clara, CA, USA) [280,281].

4.2. Two-Dimensional Electrophoresis

The detailed process was described previously [280]. In short, 10 µL of plasma (0.5 mg of protein) was mixed with 20 µL of lysis buffer (7 M urea, 2 M thiourea, 4% CHAPS, 1% DTT, 2% (v/v) amphotolys, pH 3–10, protease inhibitor cocktail) and then with 100 µL of rehydrating buffer (7 M urea, 2 M thiourea, 2% CHAPS, 0.3% DTT, 0.5% IPG (v/v) buffer, pH 3–11 NL, 0.001% bromophenol blue). Immobiline DryStrip 3–11 NL (7 cm) was passively rehydrated by this solution for 4 h at 4 °C. IEF was run on Hoefer™ IEF100 (“Thermo Fisher Scientific”, Waltham, MA, USA). After IEF, strips were incubated 10 min in the equilibration solution (50 mM Tris, pH 8.8, 6 M urea, 2% SDS, 30% (v/v) glycerol, 1% DTT), following in the same solution with 5% IAM instead of DTT. The strips were sealed with a hot solution of 0.5% agarose prepared in electrode buffer (25 mM Tris, pH 8.3, 200 mM glycine, and 0.1% SDS) on top of the polyacrylamide gel (14%), and run in the second direction [280]. Gels stained by Coomassie Blue R350 were scanned by ImageScanner III and analyzed using Image Master 2D Platinum 7.0. For the sectional 2DE analysis, this gel was cut into 96 sections with determined coordinates. Each section (~0.7 cm²) was shredded and treated
with trypsin. Tryptic peptides were eluted from the gel by extraction solution (5% (v/v) ACN, 5% (v/v) formic acid) and dried in Speed Vac. In the case of a semi-virtual 2DE, the 18-cm Immobiline DryStrip 3–11 NL was cut into 36 equal sections after IEF. For complete reduction, 300 µL of 3 mM DTT and 100 mM ammonium bicarbonate were added to each section and incubated at 50 °C for 15 min. For alkylation, 20 µL of 100 mM IAM were added and samples were incubated in the dark at r.t. for 15 min. The peptides were eluted with 60% acetonitrile and 0.1% TFA and dried in Speed Vac.

4.3. ESI LC-MS/MS Analysis

A detailed procedure was described previously [279,280]. Peptides were dissolved in 5% (v/v) formic acid. Tandem mass spectrometry analysis was conducted in duplicate on an Orbitrap Q-Exactive mass spectrometer (“Thermo Fisher Scientific”, Waltham, MA, USA). The data were analyzed by Mascot “2.4.1” (“Matrix Sciences”, Mount Prospect, IL, USA) or SearchGui [282] using the following parameters: enzyme—trypsin; maximum of missed cleavage sites—2; fixed modifications—carbamidomethylation of cysteine; variable modifications—oxidation of methionine, phosphorylation of serine, threonine, tryptophan, acetylation of lysine; the precursor mass error—10 ppm; the product mass error—0.01 Da. As a protein sequence database, UniProt (October 2014) was used.

Only 100% confident results of protein identification were selected. Two unique peptides per protein were required for all protein identifications. Exponentially modified PAI (emPAI), the exponential form of protein abundance index (PAI) defined as the number of identified peptides divided by the number of theoretically observable tryptic peptides for each protein, was used to estimate protein abundance [283].

4.4. Immunostaining (Western Blotting)

Plasma proteins (0.5 mg) were run by 2DE (cm 2DE, using 13-cm strip pH 4–7). Proteins were transferred (2 h, 28 V) from the gel onto PVDF membrane (Hybond P, 0.2 µm) using two sheets of thick paper (Bio-Rad, Hercules, CA, USA), saturated with 48 mM Tris, 39 mM glycine, 0.037% SDS, 20% ethanol. The membrane was treated following a protocol of Blue Dry Western [36] and treated with antibodies [21]. Primary antibodies were mouse monoclonal anti-Hp (C8, sc-376893, or F8, sc-390962, from “Santa Cruz Biotechnology”, Santa Cruz, CA, USA) in dilution 1/25 (80 ng/mL in TBS (25 mM), Tris (pH 7.5) and 150 mM NaCl containing 3% (w/v) BSA) or rabbit polyclonal anti-Hp (MBS177476, MyBioSource, San Diego, CA, USA). Secondary goat anti-mouse immunoglobulins G labeled by horseradish peroxidase (NA931V, “GE Healthcare”, Chicago, IL, USA) were used in TBS containing 3% (w/v) nonfat dry milk (1/5000 dilution). The reaction was developed using ECL (Western Lightning Ultra, “PerkinElmer”, Waltham, MA, USA) and X-ray film (Amersham Hyper film ECL).

5. Conclusions

For now, proteomics is collecting big data about the human plasma proteome http://plasmaproteomedatabase.org/index.html accessed on 10 September 2022 [284]. These data include many proteome parameters: their dynamics, different protein presence, abundance, modifications, variations, etc. In the case of cancer, a proteome performs multiple perturbations, where all its components are involved through changes in their levels and modifications. Here, the plasma proteome works as a united entity that executes and reflects the processes in the human body. Accordingly, the profiling of plasma proteomes is a promising and powerful approach to follow these processes. This profiling could combine hundreds of already known plasma biomarkers and has a very promising future in biomedicine as it could disclose information about any abnormal situation in the human body including cancer. There is a big chance that MS-based proteomics will become a part of the routine medical technique [14,285]. In addition to the usual MS analysis of proteins/proteoforms, this technique should include special processing programs allowing conclusions to be made about the human body’s state based on these variations in...
protein/proteoform signatures/profiles (level, PTMs, etc.). In our work, we collected information about the connection of cancers with levels of “classical plasma proteins” and generated their proteoform profiles (Table 1, Supplementary Figure S1). As a next step, similar profiles representing protein perturbations in plasma produced in the case of different cancers should be generated. Moreover, based on this information, different test systems can be developed.

**Supplementary Materials:** The following supporting information can be downloaded at: [https: //www.mdpi.com/article/10.3390/ijms231911113/s1.](https: //www.mdpi.com/article/10.3390/ijms231911113/s1.)

**Author Contributions:** Conceptualization, S.N.; validation, N.R., E.Z. and V.Z.; formal analysis, N.R., E.Z., N.K., F.K. and V.Z.; investigation, N.R., E.Z. and V.Z.; data curation, N.R., E.Z., N.K. and V.Z.; writing, S.N.; visualization, N.R. and E.Z.; supervision, S.N.; project administration, S.N. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Local Ethics Committee of Petersburg Institute of Nuclear Physics (PNPI) of National Research Center “Kurchatov Institute” (protocol code 02_2020 from 21 April 2020).

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** Not applicable.

**Acknowledgments:** The work was performed within the framework of the Program for Basic Research in the Russian Federation for a long-term period (2021–2030) (№ 122030100168-2). Mass spectrometry measurements were performed using the equipment of the “Human Proteome” Core Facilities of the Institute of Biomedical Chemistry (Moscow, Russia).

**Conflicts of Interest:** The authors declare no conflict of interest.

**Abbreviations**

- **MS**: Mass spectrometry
- **ESI LC-MS/MS**: Liquid chromatography–electrospray ionization tandem mass spectrometry
- **GBM**: Glioblastoma multiform
- **2DE**: Two-dimensional gel electrophoresis
- **emPAI**: Exponentially modified protein abundance index
- **HCC**: Hepatocellular carcinoma
- **CRC**: Colorectal cancer
- **NSCLC**: Non-small cell lung cancer
- **SCLC**: Small cell lung carcinoma
- **HDL**: High-density lipoproteins
- **cSCC**: Cutaneous squamous cell carcinoma
- **BC**: Breast cancer
- **OC**: Ovarian cancer
- **PDAC**: Pancreatic cancer
- **OSCC**: Oral squamous cell carcinoma
- **GC**: Gastric cancer
- **MM**: Multiple myeloma
- **PC**: Prostate cancer

**References**

1. Bhatt, A.N.; Mathur, R.; Farooque, A.; Verma, A.; Dwarakanath, B.S. Cancer biomarkers—Current perspectives. *Indian J. Med. Res.* 2010, 132, 129–149. [PubMed]

2. Polanski, M.; Anderson, N.L. A List of Candidate Cancer Biomarkers for Targeted Proteomics. *Biomark. Insights* 2006, 1, 117727190600100. [CrossRef]

3. Malati, T. Tumour markers: An overview. *Indian J. Clin. Biochem.* 2007, 22, 17–31. [CrossRef] [PubMed]
4. Paik, Y.K.; Kim, H.; Lee, E.Y.; Kwon, M.S.; Cho, S.Y. Overview and introduction to clinical proteomics. Methods Mol. Biol. 2008, 428, 1–31. [PubMed]
5. Nanjappa, V.; Thomas, J.K.; Marimuthu, A.; Muthusamy, B.; Radhakrishnan, A.; Sharma, R.; Ahmad Khan, A.; Balakrishnan, L.; Sahasrabuddhe, N.A.; Kumar, S.; et al. Plasma Proteome Database as a resource for proteomics research: 2014 update. Nucleic Acids Res. 2014, 42, D959–D965. [CrossRef]
6. Luque-Garcia, J.L.; Neubert, T.A. Sample preparation for serum/plasma profiling and biomarker identification by mass spectrometry. J. Chromatogr. A 2007, 1153, 259–276. [CrossRef]
7. Paulovich, A.G.; Whiteaker, J.R.; Hoofnagle, A.N.; Wang, P. The interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipeline. Proteom. Clin. Appl. 2008, 2, 1386–1402. [CrossRef]
8. Omenn, G.S.; States, D.J.; Adamski, M.; Blackwell, T.W.; Menon, R.; Hermjakob, H.; Apweiler, R.; Haab, B.B.; Simpson, R.J.; Edds, J.S.; et al. Overview of the HUPO Plasma Proteome Project: Results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 2005, 5, 3226–3245. [CrossRef]
9. Surinova, S.; Schiess, R.; Hüttenhain, R.; Cerciello, F.; Wollscheid, B.; Aebersold, R. On the development of plasma protein biomarkers. J. Proteome Res. 2011, 10, 5–16. [CrossRef]
10. Parker, C.E.; Borchers, C.H. Mass spectrometry based biomarker discovery, verification, and validation—Quality assurance and control of protein biomarker assays. Mol. Oncol. 2014, 8, 840–858. [CrossRef]
11. Hochstrasser, D.F.; Sanchez, J.-C.; Appel, R.D. Proteomics and its trends facing nature’s complexity. Proteomics 2002, 2, 807–812. [CrossRef]
12. Petricoin, E.F.; Ardekani, A.M.; Hitt, B.A.; Levine, P.; Fusaro, V.; Steinberg, S.M.; Mills, G.B.; Simone, C.; Fishman, D.A.; Kohn, E.C.; et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 359, 572–577. [CrossRef]
13. Schiess, R.; Wollscheid, B.; Aebersold, R. Targeted proteomic strategy for clinical biomarker discovery. Mol. Oncol. 2009, 3, 33–44. [CrossRef][PubMed]
14. Geyer, P.E.; Kulak, N.A.; Pichler, G.; Holdt, L.M.; Teupser, D.; Mann, M. Plasma Proteome Profiling to Assess Human Health and Disease. Cell Syst. 2016, 2, 185–195. [CrossRef][PubMed]
15. Geyer, P.E.; Holdt, L.M.; Teupser, D.; Mann, M. Revisiting biomarker discovery by plasma proteomics. Mol. Syst. Biol. 2017, 13, 942. [CrossRef]
16. Farrah, T.; Deutsch, E.W.; Omenn, G.S.; Campbell, D.S.; Sun, Z.; Bletz, J.A.; Mallick, P.; Katz, J.E.; Malmström, J.; Ossola, R.; et al. A high-confidence human plasma proteome reference set with estimated concentrations in PeptideAtlas. Mol. Cell. Proteom. 2011, 10, M110.006353. [CrossRef][PubMed]
17. Cox, J.; Hein, M.Y.; Luberc, C.A.; Paron, I.; Nagaraj, N.; Mann, M. Accurate Proteome-wide Label-free Quantification by Delayed Normalization and Maximal Peptide Ratio Extraction, Termined MaxLFQ. Mol. Cell. Proteom. 2014, 13, 2513–2526. [CrossRef][PubMed]
18. Ray, S.; Patel, S.K.; Kumar, V.; Daamahe, J.; Srivastava, S. Differential expression of serum/plasma proteins in various infectious diseases: Specific or nonspecific signatures. Proteomics Clin. Appl. 2014, 8, 53–72. [CrossRef]
19. Anderson, N.L.; Anderson, N.G. The Human Plasma Proteome: History, Character, and Diagnostic Prospects. Mol. Cell. Proteom. 2002, 1, 845–867. [CrossRef][PubMed]
20. Hortin, G.L.; Sviridov, D.; Anderson, N.L. High-abundance polypeptides of the human plasma proteome comprising the top 4 logs of polypeptide abundance. Clin. Chem. 2008, 54, 1608–1616. [CrossRef][PubMed]
21. Silva-Costa, L.C.; Garcia-Rosa, S.; Smith, B.J.; Baldasso, P.A.; Steiner, J.; Martins-de-Souza, D. Blood plasma high abundant protein depletion unintentionally carries over 100 proteins. Sep. Sci. PIUS 2019, 2, 449–456. [CrossRef]
22. Anderson, L.; Anderson, N.G. High resolution two-dimensional electrophoresis of human plasma proteins. Proc. Natl. Acad. Sci. USA 1977, 74, 5421–5425. [CrossRef]
23. Anderson, N.G.; Anderson, L. The Human Protein Index. Clin. Chem. 1982, 28, 739–748. [CrossRef][PubMed]
24. Anderson, N.G.; Matheson, A.; Anderson, N.L. Back to the future: The human protein index (HPI) and the agenda for post-proteomic biology. Proteomics. 2001, 1, 3–12. [CrossRef]
25. Ciereszko, A.; Dietrich, M.A.; Słowińska, M.; Nynca, J.; Ciborowski, M.; Kislok, J.; Michalska-Falkowska, A.D.; Reszec, J.; Sierko, E.; Nikiforowski, J.; Identification of protein changes in the blood plasma of lung cancer patients subjected to chemotherapy using a 2-DIGE approach. PLoS ONE 2019, 14, e0223840. [CrossRef]
26. Kondo, T. Cancer biomarker development and two-dimensional difference gel electrophoresis (2D-DIGE). Biochim. Biophys. Acta 2019, 1867, 2–8. [CrossRef][PubMed]
27. Winden, A.W.O.-V.; Krop, E.J.; Käredal, M.H.; Gast, M.-C.W.; Lindh, C.H.; Jeppsson, M.C.; Jönsson, B.A.; E Grobbee, D.; Peeters, P.H.; Beijnen, J.H.; et al. Searching for early breast cancer biomarkers by serum protein profiling of pre-diagnostic serum: a nested case-control study. BMC Cancer 2011, 11, 381.
28. Looi, M.L.; Karsani, S.A.; Rahman, M.A.; Dali, A.Z.H.M.; Ali, S.A.M.; Ngah, W.Z.W.; Yusof, Y.A.M. Plasma proteome analysis of cervical intraepithelial neoplasia and cervical squamous cell carcinoma. J. Biosci. 2009, 34, 917–925. [CrossRef][PubMed]
29. Ura, B.; Biffi, S.; Monasta, L.; Arrigoni, G.; Battisti, I.; Di Lorenzo, G.; Romano, F.; Aloisio, M.; Celsi, F.; Addobbati, R.; et al. Two Dimensional-Difference in Gel Electrophoresis (2D-DIGE) Proteomic Approach for the Identification of Biomarkers in Endometrial Cancer Serum. Cancers 2021, 13, 3639. [CrossRef]
30. Naryzhny, S.; Klopop, N.; Ronzhina, N.; Zorina, E.; Zgoda, V.; Kleyst, O.; Belyakova, N.; Legina, O. A database for inventory of proteome profiles: “2DE-pattern”. Electrophoresis 2020, 41, 1118–1124. [CrossRef]
31. Ahmed, F.E. Sample preparation and fractionation for proteome analysis and cancer biomarker discovery by mass spectrometry. J. Sep. Sci. 2009, 32, 771–798. [CrossRef]
32. Abramson, F.P.; Jenkins, J.; Ostchega, Y. Effects of cancer and its treatments on plasma concentration of alpha 1-acid glycoprotein and propanolol binding. Clin. Pharmacol. Ther. 1982, 32, 659–663. [CrossRef]
33. Pontén, F.; Jirstöm, K.; Uhlen, M. The Human Protein Atlas—A tool for pathology. J. Pathol. 2008, 216, 387–393. [CrossRef]
34. Janciakusiene, S.; Wrenger, S.; Günzel, S.; Gründing, A.R.; Golpon, H.; Welle, T. Potential Roles of Acute Phase Proteins in Cancer: Why Do Cancer Cells Produce or Take Up Exogenous Acute Phase Protein Alpha-1-Antitrypsin? Front. Oncol. 2021, 11, 622076. [CrossRef]
35. Elpek, G.O. Orosomucoid in liver diseases. World J. Gastroenterol. 2021, 27, 7739–7747. [CrossRef]
36. Fischer, K.; Kettunen, J.; Würtz, P.; Haller, T.; Havulinna, A.S.; Kangas, A.J.; Soininen, P.; Esko, T.; Tammeeso, M.-L.; Mägi, R.; et al. Biomarker profiling by nuclear magnetic resonance spectroscopy for the prediction of all-cause mortality: An observational study of 17,345 persons. PLoS Med. 2014, 11, e1001606. [CrossRef]
37. Ayyub, A.; Saleem, M.; Fatima, I.; Tariq, A.; Hashmi, N.; Musharraf, S.G. Glycosylated Alpha-1-acid glycoprotein 1 as a potential lung cancer serum biomarker. Int. J. Biochem. Cell Biol. 2016, 70, 68–75. [CrossRef]
38. Jabir, R.S.; Ho, G.F.; Annuar, M.A.B.A.; Stanslas, J. Plasma alpha-1-acid glycoprotein as a potential predictive biomarker for non-haematological adverse events of docetaxel in breast cancer patients. Biomarkers 2018, 23, 142–146. [CrossRef]
39. Balmaña, M.; Giménez, E.; Puerta, A.; Llop, E.; Figueras, J.; Fort, E.; Sanz-Nebot, V.; de Bolós, C.; Rizzi, A.; Barrabés, S.; et al. Increased α1-3 fucosylation of α1-1-acid glycoprotein (AGP) in pancreatic cancer. J. Proteom. 2016, 132, 144–154. [CrossRef]
40. Tanabe, K.; Kitagawa, K.; Kojima, N.; Iijima, S. Multifucosylated Alpha-1-acid Glycoprotein as a Novel Marker for Hepatocellular Carcinoma. J. Proteome Res. 2016, 15, 2935–2944. [CrossRef]
41. Gao, F.; Zhang, X.; Whang, S.; Zheng, C. Prognostic impact of plasma ORM2 levels in patients with stage II colorectal cancer. Ann. Clin. Lab. Sci. 2014, 44, 388–393. [PubMed]
42. Anders, C.L.; Ponte, A.; Kueppers, F. The Effects of Inflammation on Alpha 1 Antitrypsin Levels in a National Screening Cohort. COPD J. Chronic Obstr. Pulm. Dis. 2016, 15, 10–16. [CrossRef] [PubMed]
43. Torres-Durán, M.; Lopez-Campos, J.L.; Barrecheguren, M.; Miravitles, M.; Martinez-Delgado, B.; Castillo, S.; Escribano, A.; Baloi, A.; Navarro-Garcia, M.M.; Pellicer, D.; et al. Alpha-1 antitrypsin deficiency: Outstanding questions and future directions. Orphanet J. Rare Dis. 2018, 13, 114. [CrossRef]
44. Ercetin, E.; Richtmann, S.; Delgado, B.M.; Gomez-Mariano, G.; Wrenger, S.; Korenbaum, E.; Liu, B.; DeLuca, D.; Kühl, M.P.; Jonigk, D.; et al. Clinical Significance of SERPINA1 Gene and Its Encoded Alpha-antitrypsin Protein in NSCLC. Cancers 2019, 11, 1306. [CrossRef]
45. Pérez-Holanda, S.; Blanco, I.; Menéndez, M.; Rodrigo, L. Serum concentration of alpha-1 antitrypsin is significantly higher in colorectal cancer patients than in healthy controls. BMC Cancer 2014, 14, 355. [CrossRef]
46. Brkic, S.; Salkic, A.; Nuhbegovic, S.; Brkic, F.; Umihanic, S. Influence of surgical therapy on serum values of alpha 1-antitrypsin in patients with head and neck tumors. Med. Arh. 2011, 65, 99–101. [CrossRef]
47. Jaberie, H.; Hosseini, S.V.; Nāghibalhosaini, F. Evaluation of Alpha 1-Antitrypsin for the Early Diagnosis of Colorectal Cancer. Pathol. Oncol. Res. 2020, 26, 1165–1173. [CrossRef]
48. Repetto, O.; De Re, V.; Mussolin, L.; Tedeschi, M.; Elia, C.; Bianchi, M.; Buffardi, S.; Sala, A.; Burnelli, R.; Mascarín, M. Proteomic Profiles and Biological Processes of Relapsed vs. Non-Relapsed Pediatric Hodgkin Lymphoma. Int. J. Mol. Sci. 2020, 21, 2185. [CrossRef]
49. Liang, Y.; Ma, T.; Thakur, A.; Yu, H.; Gao, L.; Shi, P.; Li, X.; Ren, H.; Jia, L.; Zhang, S.; et al. Differentially expressed glycosylated patterns of α1-antitrypsin as serum biomarkers for the diagnosis of lung cancer. Glycobiology 2015, 25, 331–340. [CrossRef]
50. Wu, C.-C.; Lu, Y.-T.; Yeh, T.-S.; Chan, Y.-H.; Dash, S.; Yu, J.-S. Identification of Fucosylated SERPINA1 as a Novel Plasma Marker for Pancreatic Cancer Using Lectin Affinity Capture Coupled with iTRAQ-Based Quantitative Glycoproteomics. Int. J. Mol. Sci. 2021, 22, 6079. [CrossRef]
51. Liu, Y.; Luo, X.; Hu, H.; Wang, R.; Sun, Y.; Zeng, R.; Chen, H. Integrative proteomics and tissue microarray profiling indicate the association between overexpressed serum proteins and non-small cell lung cancer. PLoS ONE 2012, 7, e51748. [CrossRef] [PubMed]
52. Kopylov, A.T.; Stepanov, A.A.; Malsagova, K.A.; Soni, D.; Kushlinsky, N.E.; Enikeev, D.V.; Potolodykova, N.V.; Litsitsa, A.V.; Kaysheva, A.L. Revelation of Proteomic Indicators for Colorectal Cancer in Initial Stages of Development. Molecules 2020, 25, 619. [CrossRef] [PubMed]
53. Canales, N.A.G.; Marina, V.M.; Castro, J.S.; Jiménez, A.A.; Mendoza-Hernández, G.; McCarron, E.L.; Roman, M.B.; Castro-Romero, J.I. A1BG and C3 are overexpressed in patients with cervical intraepithelial neoplasia III. Oncol. Lett. 2014, 8, 939–947. [CrossRef] [PubMed]
54. Kim, J.H.; Kim, Y.-W.; Kim, I.-W.; Park, D.C.; Kim, Y.W.; Lee, K.-H.; Jang, C.K.; Ahn, W.S. Identification of candidate biomarkers using the Experion™ automated electrophoresis system in serum samples from ovarian cancer patients. Int. J. Oncol. 2013, 42, 1257–1262. [CrossRef] [PubMed]
55. Gaziev, U.M.; Kit, O.I.; Franstsiyants, E.M.; Kozlova, L.; Mezentsev, S.S. Alpha-2-macroglobulin as the marker for pancreatic cancer process direction. J. Clin. Oncol. 2016, 34, e15686. [CrossRef]
56. Boccellino, M.; Pinto, F.; Ieluzzi, V.; Giovane, A.; Quagliuolo, L.; Fariello, C.; Coppola, M.; Carlucci, A.; Santini, M.; Ferati, K.; et al. Proteomics analysis of human serum of patients with non-small-cell lung cancer reveals proteins as diagnostic biomarker candidates. J. Cell. Physiol. 2019, 234, 23798–23806. [CrossRef]

57. Taguchi, O.; Gabazza, E.C.; Yoshida, M.; Yamakami, T.; Kobayashi, H.; Shima, T. High plasma level of plasmin-alpha 2-plasmin inhibitor complex is predictor of poor prognosis in patients with lung cancer. Clin. Chim. Acta 1996, 249, 69–81. [CrossRef]

58. Cavalcante, M.d.S.; Torres-Romero, J.C.; Lobo, M.D.P.; Moreno, F.B.M.B.; Bezerra, L.P.; Lima, D.S.; Matos, J.C.; Moreira, R.d.A.; Monteiro-Moreira, A.C.d.O. A panel of glycoproteins as candidate biomarkers for early diagnosis and treatment evaluation of B-cell acute lymphoblastic leukemia. Biomark. Res. 2016, 4, 1. [CrossRef]

59. Zhang, Q.; Huang, R.; Tang, Q.; Yu, Y.; Huang, Q.; Chen, Y.; Wang, G.; Wang, X. Leucine-rich alpha-2-glycoprotein-1 is up-regulated in colorectal cancer and is a tumor promoter. Oncotargets Ther. 2018, 11, 2745–2752. [CrossRef]

60. Ivancic, M.M.; Megna, B.W.; Sverchikhov, Y.; Craven, M.; Reichelderfer, M.; Pickhardt, P.J.; Sussman, M.R.; Kennedy, G.D. Noninvasive Detection of Colorectal Carcinomas Using Serum Protein Biomarkers. J. Surg. Res. 2020, 246, 160–169. [CrossRef]

61. Guldvik, I.J.; Zuber, V.; Bradland, P.R.; Grytli, H.H.; Ramberg, H.; Lilleby, W.; Thiede, B.; Zucknick, M.; Saatcioglu, F.; Gislefoss, R.; et al. Identification and Validation of Leucine-rich alpha-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification. Eur. Urol. Open Sci. 2020, 21, 51–60. [CrossRef] [PubMed]

62. Stenman, U.H.; Leinonen, J.; Alifth, H.; Rannikko, S.; Tuhkanen, K.; Alifth, O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res. 1991, 51, 222–226. [PubMed]

63. Jin, Y.; Wang, W.; Wang, Q.; Zhang, Y.; Zahid, K.R.; Raza, U.; Gong, Y. Alpha-1-antichymotrypsin as a novel biomarker for diagnosis, prognosis, and therapy prediction in human diseases. Cancer Cell Int. 2022, 22, 156. [CrossRef] [PubMed]

64. Chang, T.-T.; Ho, C.-H. Plasma proteome atlas for differentiating tumor stage and post-surgical prognosis of hepatocellular carcinoma. Acta Clin. Res. Hepatol. Gastroenterol. 2021, 1051–1058. [CrossRef] [PubMed]

65. Li, H.; Sun, L.; Chen, L.; Kang, Z.; Hao, G.; Bai, F. Effects of adiponectin, plasma D-dimer, inflammation and tumor markers on clinical characteristics and prognosis of patients with ovarian cancer. J. Med. Biochem. 2020, 41, 71–78. [CrossRef] [PubMed]

66. Dieplinger, H.; Dieplinger, B. Afamin—A pleiotropic glycoprotein involved in various disease states. Clin. Chim. Acta 2018, 446, 105–110. [CrossRef]

67. Melmer, A.; Fineder, L.; Lamina, C.; Kollerits, B.; Dieplinger, B.; Braicu, I.; Sehouli, J.; Cadron, I.; Vergote, I.; Mahner, S.; et al. Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer—a study by the OVCAD consortium. Gynecol. Oncol. 2013, 128, 38–43. [CrossRef]

68. Dieplinger, H.; Ankerst, D.P.; Burges, A.; Lenhard, M.; Lingenhel, A.; Fineder, L.; Buchner, H.; Stieber, P. Afamin and apolipoprotein A-IV: Novel protein markers for ovarian cancer. Cancer Epidemiol. Biomark. Prev. A Publ. Am. Assoc. Cancer Res. Cospnsored Am. Soc. Prev. Oncol. 2009, 18, 1127–1133. [CrossRef]

69. Chiang, T.-T.; Ho, C.-H. Plasma proteome atlas for differentiating tumor stage and post-surgical prognosis of hepatocellular carcinoma and cholangiocarcinoma. PLoS ONE 2020, 15, e0238251. [CrossRef]

70. Humphries, J.M.; Penno, M.A.S.; Weiland, F.; Klingler-Hoffmann, M.; Zuber, A.; Boussiotas, A.; Ernst, M.; Hoffmann, P. Identification and validation of novel candidate plasma protein biomarkers for the detection of human gastric cancer. Biochim. Biophys. Acta 2014, 1844, 1051–1058. [CrossRef]

71. Oñate-Ocaña, L.F.; Aiello-Crocifoglio, V.; Gallardo-Rincón, D.; Herrera-Goeppert, R.; Brom-Valladares, R.; Carrillo, J.F.; Cervera, E.; Mohar-Betancourt, A. Low serum albumin with increased long-term mortality in various malignancies, including breast, lung, gastric, colorectal, and pancreatic cancer. Ann. Surg. Oncol. 2007, 14, 381–389. [CrossRef]

72. Lis, C.G.; Grutsch, J.F.; Vashi, P.G.; Lammersfeld, C.A. Is serum albumin an independent predictor of survival in patients with breast cancer? J. Parenter. Enter. Nutr. 2003, 27, 10–15. [CrossRef] [PubMed]

73. Boonpipattanapong, T.; Chewatanakornkul, S. Preoperative carcinoembryonic antigen and albumin in predicting survival in patients with colon and rectal carcinomas. J. Clin. Gastroenterol. 2006, 40, 592–595. [CrossRef]

74. Suh, B.; Park, S.; Shin, D.W.; Yun, J.M.; Keam, B.; Yang, H.-K.; Ahn, E.; Lee, H.; Park, J.H.; Cho, B. Low albumin-to-globulin ratio associated with cancer incidence and mortality generally in healthy adults. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2014, 25, 2260–2266. [CrossRef] [PubMed]

75. Fujii, T.; Tokuda, S.; Nakazawa, Y.; Kurozumi, S.; Obayashi, S.; Yajima, R.; Shirabe, K. Implications of Low Serum Albumin as a Prognostic Factor of Long-term Outcomes in Patients With Breast Cancer. In Vivo 2020, 34, 2033–2036. [CrossRef] [PubMed]

76. Cohen, A.; Wang, E.; Chisholm, K.A.; Kostyleva, R.; O’Connor-McCourt, M.; Pinto, D.M. A mass spectrometry-based plasma protein panel targeting the tumor microenvironment in patients with breast cancer. J. Proteom. 2013, 81, 135–147. [CrossRef] [PubMed]

77. Pugia, M.J.; Valdes, R.; Jortani, S.A. Bikunin (Urinary Trypsin Inhibitor): Structure, Biological Relevance, And Measurement. In Advances in Clinical Chemistry; Elsevier: Amsterdam, The Netherlands, 2007; Volume 44, pp. 223–245. [CrossRef]

78. Lu, Z.; Wang, F.; Liang, M. SerpinC1/Antithrombin III in kidney-related diseases. Clin. Sci. 2017, 131, 823–831. [CrossRef]

79. Cao, X.; Cao, Z.; Ou, C.; Zhang, L.; Chen, Y.; Li, Y.; Zhu, B.; Shu, H. Combination of serum paraoxonase/arylesterase 1 and antithrombin-III is a promising non-invasion biomarker for discrimination of AFP-negative HCC versus liver cirrhosis patients. Clin. Res. Hepatol. Gastroenterol. 2021, 45, 101583. [CrossRef]
80. Ren, L.; Yi, J.; Li, W.; Zheng, X.; Liu, J.; Wang, J.; Du, G. Apolipoproteins and cancer. *Cancer Med.* 2019, 8, 7032–7043. [CrossRef]
81. Georgi, K.; Vyrla, D.; Drakos, E. Apolipoprotein A-I (ApoA-I), Immunity, Inflammation and Cancer. *Cancers* 2019, 11, 1097. [CrossRef] [PubMed]
82. Chang, S.-C.; Lin, W.-L.; Chang, Y.-F.; Lee, C.-T.; Wu, J.-S.; Hsu, P.-H.; Chang, C.-F. Glycoproteomic identification of novel plasma biomarkers for oral cancer. *J. Food Drug Anal.* 2019, 27, 483–493. [CrossRef] [PubMed]
83. Shi, C.; Gong, S.; Wu, A.; Yang, S.; Zou, D.; Zhang, Y.; Wu, N.; Ma, C.; Shi, S.; Chen, Y.; et al. Decreased serum apolipoprotein A1 level predicts poor prognosis of patients with de novo myelodysplastic syndromes. *BMC Cancer* 2022, 22, 127. [CrossRef] [PubMed]
84. Cheng, T.; Dai, X.; Zhou, D.-L.; Lv, Y.; Miao, L.-Y. Correlation of apolipoprotein A-I kinetics with survival and response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer. *Med. Oncol.* 2015, 32, 407. [CrossRef] [PubMed]
85. Chang, H.; Wei, J.-W.; Chen, K.; Zhang, S.; Han, F.; Lu, L.-X.; Xiao, W.-W.; Gao, Y.-H. Apolipoprotein A-I Is a Prognosticator of Nasopharyngeal Carcinoma in the Era of Intensity-Modulated Radiotherapy. *J. Cancer* 2018, 9, 702–710. [CrossRef]
86. Wang, X.-P.; Li, X.-H.; Zhang, L.; Lin, J.-H.; Huang, H.; Kang, T.; Mao, M.-J.; Chen, H.; Zheng, X. High level of serum apolipoprotein A-I is a favorable prognostic factor for overall survival in esophageal squamous cell carcinoma. *BMC Cancer* 2016, 16, 516. [CrossRef] [PubMed]
87. Hachem, H.; Favre, G.; Ghalim, N.; Puchois, P.; Fruchart, J.C.; Soulou, G. Quantitative abnormalities of lipoprotein particles in multiple myeloma. *J. Clin. Chem. Clin. Biochem.* 2007, 25, 675–679. [CrossRef]
88. Liu, Y.; Sogawa, K.; Sunaga, M.; Umemura, H.; Satoh, M.; Kazumi, T.; Yoshihikawa, M.; Tomonaga, T.; Yokosuka, O.; Nomura, F. Increased concentrations of apo A-I and apo A-II fragments in the serum of patients with hepatocellular carcinoma by magnetic beads-assisted MALDI-TOF mass spectrometry. *Ann. J. Clin. Pathol.* 2014, 111, 52–61. [CrossRef] [PubMed]
89. Malik, G.; Ward, M.D.; Gupta, S.K.; Trosset, M.W.; E Grizzle, W.; Adam, B.-L.; I Diaz, J.; Sillevis Smitt, P.A.E.; Luider, T.H.; Pieters, R. Identification of apolipoprotein A-II in cerebrospinal fluid of pediatric brain tumor patients by protein expression profiling. *Clin. Chem.* 2006, 52, 1501–1509. [CrossRef]
90. Honda, K.; Okusaka, T.; Felix, K.; Nakamori, S.; Sata, N.; Nagai, H.; Ioka, T.; Tsuchida, A.; Shimahara, T.; Shimahara, M.; et al. Altered plasma apolipoprotein modifications in patients with pancreatic cancer: Protein characterization and multi-institutional validation. *PloS ONE* 2012, 7, e46908. [CrossRef]
91. Bharali, D.; Banerjee, B.D.; Bharadwaj, M.; Husain, S.A.; Kar, P. Expression analysis of apolipoproteins AI & AIV in hepatocellular carcinoma: A protein-based hepatocellular carcinoma-associated study. *Indian J. Med. Res.* 2018, 147, 361–368. [CrossRef]
92. Farrokh, R.; Arlef Oskouie, A.; Rezaei Tavirani, M.; Mohajeri-Tehrani, M.R.; Soroush, A.R. Decreased apolipoprotein A4 and increased complement component 3 as potential markers for papillary thyroid carcinoma: A proteomic study. *Int. J. Biol. Markers* 2018, 33, 455–462. [CrossRef] [PubMed]
93. Li, B.; An, H.J.; Kirmiz, C.; Lebrilla, C.B.; Lam, K.S.; Miyamoto, S. Glycoproteomic analyses of ovarian cancer cell lines and sera from ovarian cancer patients show distinct glycosylation changes in individual proteins. *J. Proteome Res.* 2008, 7, 3776–3788. [CrossRef] [PubMed]
94. Wang, M.; Wang, J.; Jiang, H. Diagnostic value of apolipoprotein C-II, transhyretin and apolipoprotein C-III in gastric cancer. *OncoLett* 2019, 17, 3227–3232. [CrossRef]
95. Yi, J.; Ren, L.; Wu, J.; Li, W.; Zheng, X.; Du, G.; Wang, J. Apolipoprotein C1 (APOC1) as a novel diagnostic and prognostic biomarker for gastric cancer. *Ann. Transl. Med.* 2019, 7, 380. [CrossRef] [PubMed]
96. Zhou, Y.; Luo, G. Apolipoproteins, as the carrier proteins for lipids, are involved in the development of breast cancer. *Clin. Transl. Oncol.* 2020, 22, 1952–1962. [CrossRef]
97. Zhao, Z.; Zou, S.; Guan, X.; Wang, M.; Jiang, Z.; Liu, Z.; Li, C.; Lin, H.; Liu, X.; Yang, R.; et al. Apolipoprotein E Overexpression Is Associated With Tumor Progression and Poor Survival in Colorectal Cancer. *Front. Genet.* 2018, 9, 650. [CrossRef] [PubMed]
98. Kemp, S.B.; Carpenter, E.S.; Steele, N.G.; Donahue, K.L.; Nwosu, Z.C.; Pacheco, A.; Velez-Delgado, A.; Menjivar, R.E.; Lima, F.; The, S.; et al. Apolipoprotein E Promotes Immune Suppression in Pancreatic Cancer through NF-κB-Mediated Production of CXCL1. *Cancer Res.* 2021, 81, 4303–4318. [CrossRef]
99. Xue, Y.; Huang, S.; Huang, J.; Li, S.; Zhang, C.; Zhou, X. Identification of Apolipoprotein E as a Potential Diagnostic Biomarker of Nasopharyngeal Carcinoma. *Cancer Manag. Res.* 2020, 12, 8943–8950. [CrossRef] [PubMed]
100. Xu, X.; Wan, J.; Yuan, L.; Ba, J.; Feng, P.; Long, W.; Huang, H.; Liu, P.; Cai, Y.; Liu, M.; et al. Serum levels of apolipoprotein E correlates with disease progression and poor prognosis in breast cancer. *Tumor Biol.* 2016, 37, 15959–15966. [CrossRef] [PubMed]
101. Wang, Y.-B.; Zhou, B.-X.; Ling, Y.-B.; Xiong, Z.-Y.; Li, R.-X.; Zhong, Y.-S.; Xu, M.-X.; Lu, Y.; Liang, H.; Chen, G.-H.; et al. Decreased expression of ApoE associates with poor prognosis in human hepatocellular carcinoma. *Gastroenterol. Rep.* 2019, 7, 354–360. [CrossRef] [PubMed]
102. Ding, X.; Piao, Y.-F.; Liu, Y.; Gao, P.-J. Beta-2-GPI: A novel factor in the development of hepatocellular carcinoma. *J. Cancer Res. Clin. Oncol.* 2010, 136, 1671–1680. [CrossRef] [PubMed]
103. Mandili, G.; Notarpietro, A.; Khadjavi, A.; Alassia, M.; Battaglia, A.; Lucatello, B.; Frea, B.; Turrini, F.; Novelli, F.; Giribaldi, G.; et al. Beta-2-glycoprotein-1 and alpha-1-antitrypsin as urinary markers of renal cancer in von Hippel-Lindau patients. *Biomarkers* 2018, 23, 123–130. [CrossRef] [PubMed]
155. Bruserud, O.; Aarstad, H.H.; Tvedt, T.H.A. Combined C-Reactive Protein and Novel Inflammatory Parameters as a Predictor in Cancer—What Can We Learn from the Hematological Experience? Cancers 2020, 12, 1966. [CrossRef]

156. Lee, K.; Nam, K.; Oh, S.; Lim, J.; Kim, R.K.; Shim, D.; Choi, J.; Lee, S.-J.; Yu, J.-H.; Lee, J.W.; et al. ECM1 regulates tumor metastasis and CSC-like property through stabilization of β-catenin. Oncogene 2015, 34, 6055–6065. [CrossRef] [PubMed]

157. Wang, X.; Peng, Y.; Xie, M.; Gao, Z.; Yin, L.; Yu, R.; Liu, R. Identification of extracellular matrix protein 1 as a potential plasma biomarker of ESCC by proteomic analysis using iTRAQ and 2D-LC-MS/MS. PROTEOMICS—Clin. Appl. 2017, 11, 1600163. [CrossRef] [PubMed]

158. Cheng, Y.; Liu, C.; Zhang, N.; Wang, S.; Zhang, Z. Proteomics Analysis for Finding Serum Markers of Ovarian Cancer. Biomed Res. Int. 2014, 2014, 179040. [CrossRef]

159. Gong, J.; Jie, Y.; Xiao, C.; Zhou, W.; Li, X.; Chen, Y.; Wu, Y.; Cao, J.; Zhang, Q.; Gao, Z.; et al. Increased Expression of Fibulin-1 Is Associated With Hepatocellular Carcinoma Progression by Regulating the Notch Signaling Pathway. Front. Cell Dev. Biol. 2020, 8, 478. [CrossRef]

160. Watany, M.M.; Elmashad, N.M.; Badawi, R.; Hawash, N. Serum FBLN1 and STK31 as biomarkers of colorectal cancer and their ability to noninvasively differentiate colorectal cancer from benign polyps. Clin. Chim. Acta 2018, 483, 151–155. [CrossRef]

161. Xia, H.; Feng, L.; Lin, L.; Jiang, Z.; Chen, J.; Shi, W.; Ying, S.; Yu, M.; Ju, L.; Zhu, L.; et al. Exploration of identifying novel serum biomarkers for malignant mesothelioma using iTRAQ combined with 2D-LC-MS/MS. Environ. Res. 2021, 193, 110467. [CrossRef]

162. Zhu, J.; Chen, R.; Mo, L.; Tang, H.; Kuang, Y.; Fei, W.; He, C.; Hu, X. Expression of fibulin-1 predicted good prognosis in patients with colorectal cancer. J. Transl. Med. 2015, 13, 399–347.

163. Wei, S.; Liu, W.; Xu, M.; Qin, H.; Liu, C.; Zhang, R.; Zhou, S.; Li, E.; Liu, Z.; Wang, Q. Cathepsin F and Fibulin-1 as novel diagnostic biomarkers for brain metastasis of non-small cell lung cancer. Br. J. Cancer 2022, 126, 1795–1805. [CrossRef] [PubMed]

164. Sokolowska, A.; Świerczko, A.S.; Gajek, G.; Golos, A.; Michalski, M.; Nowicki, M.; Szała-Pożdej, A.; Wolska-Washer, A.; Brzezińska, O.; Wierzbowska, A.; et al. Associations of ficolins and mannose-binding lectin with acute myeloid leukaemia in adults. Sci. Rep. 2020, 10, 10561. [CrossRef] [PubMed]

165. Li, Q.; Lin, Y. Evaluation of Ficolin-3 as a Potential Prognostic Serum Biomarker in Chinese Patients with Esophageal Cancer. Genet. Test. Mol. Biomark. 2019, 23, 565–572. [CrossRef] [PubMed]

166. Okano, T.; Kondo, T.; Kakisaka, T.; Fuji, K.; Yamada, M.; Kato, H.; Nishimura, T.; Gemma, A.; Kudoh, S.; Hirohashi, S. Plasma proteomics of lung cancer by a linkage of multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis. Proteomics 2006, 6, 3938–3948. [CrossRef] [PubMed]

167. Andersen, J.D.; Boylan, K.L.M.; Xue, F.S.; Anderson, L.B.; Witthuhn, B.A.; Markowski, T.W.; Higgins, L.; Skubitz, A.P. N. Okano, T.; Kondo, T.; Kakisaka, T.; Fujii, K.; Yamada, M.; Kato, H.; Nishimura, T.; Gemma, A.; Kudoh, S.; Hirohashi, S. Plasma proteomics of lung cancer by a linkage of multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis. Proteomics 2010, 31, 599–610. [CrossRef] [PubMed]

168. Greco, M.; Mitri, M.D.; Chiriaco, F.; Leo, G.; Brienza, E.; Maffia, M. Serum proteomic profile of cutaneous malignant melanoma and relation to cancer progression: Association to tumor derived alpha-N-acetylgalactosaminidase activity. Cancer Lett. 2009, 283, 222–229. [CrossRef]

169. Stone, L. Fetuin–A—a marker for metastatic disease? Nat. Rev. Urol. 2015, 12, 178. [CrossRef]

170. Ochieng, J.; Nangami, G.; Sakwe, A.; Moye, C.; Alvarez, J.; Whalen, D.; Thomas, P.; Lammers, J.P. Impact of Fetuin-A (AHSG) on Tumor Progression and Type 2 Diabetes. Anticancer Res. 2019, 39, 2531–2534. [CrossRef]

171. Holm, M.; Joenväärä, S.; Saraswat, M.; Mustonen, H.; Tohmola, T.; Ristimäki, A.; Renkonen, R.; Haglund, C. Identification of several plasma proteins whose levels in colorectal cancer patients differ depending on outcome. FASEB Bioadv. 2020, 7, 733–730. [CrossRef]

172. Zhang, L.; Long, Q. Elevated serum plasma fibrinogen is associated with advanced tumor stage and poor survival in hepatocellular carcinoma patients. Medicine 2017, 96, e6694. [CrossRef]

173. Bailey, M.J.; Shield-Artin, K.L.; Oliva, K.; Ayhan, M.; Reisman, S.; Rice, G.E. Stage-specific analysis of plasma protein profiles in ovarian cancer: Difference in gel electrophoresis analysis of pooled clinical samples. J. Carcinog. 2013, 12, 10. [PubMed]

174. Yang, W.; Shi, J.; Zhou, Y.; Liu, T.; Li, J.; Hong, F.; Zhang, K.; Liu, N. Co-expression Network Analysis Identified Key Proteins in Association With Hepatic Metastatic Colorectal Cancer. Proteomics Clin. Appl. 2019, 13, e1900017. [CrossRef] [PubMed]

175. Zhu, W.L.; Fan, B.L.; Liu, D.L.; Zhu, W.X. Abnormal expression of fibrinogen gamma (FGG) and plasma level of fibrinogen in patients with hepatocellular carcinoma. Anticancer Res. 2009, 29, 2531–2534. [CrossRef]

176. Peng, H.H.; Wang, J.N.; Xiao, L.F.; Yan, M.; Chen, S.P.; Wang, L.; Yang, K. Elevated Serum FGG Levels Prognosticate and Promote the Disease Progression in Prostate Cancer. Front. Genet. 2021, 12, 651647. [CrossRef] [PubMed]

177. Wang, Z.; Wang, C.; Huang, X.; Shen, Y.; Shen, J.; Ying, K. Differential proteome profiling of pleural effusions from lung cancer and benign inflammatory disease patients. Biochim. Biophys. Acta 2012, 1824, 692–700. [CrossRef] [PubMed]

178. Germer, C.; Steinkellner, W.; Holzmann, K.; Gsür, A.; Grimm, R.; Ensinger, C.; Oberst, P.; Sauermann, G. Elevated plasma levels of crosslinked fibrinogen gamma-chain dimer indicate cancer-related fibrin deposition and fibrinolysis. Thromb. Haemost. 2001, 85, 494–501. [PubMed]

179. Tas, F.; Bilgin, E.; Karabulut, S.; Tastekin, D.; Duranýildız, D. Levels of serum fibronectin as a biomarker in gastric cancer patients: Correlation with clinical diagnosis and outcome. Mol. Clin. Oncol. 2016, 4, 655–659. [CrossRef] [PubMed]

180. Moon, P.-G.; Lee, J.-E.; Cho, Y.-E.; Lee, S.J.; Chae, Y.S.; Jung, J.H.; Kim, I.-S.; Park, H.Y.; Baek, M.-C. Fibronectin on circulating extracellular vesicles as a liquid biopsy to detect breast cancer. Oncotarget 2016, 7, 40189–40199. [CrossRef] [PubMed]
206. Hamm, A.; Veeck, J.; Bektas, N.; Wild, P.J.; Hartmann, A.; Heindrichs, U.; Kristiansen, G.; Werbowski-Ogilvie, T.; Del Maestro, R.; Knuechel, R.; et al. Frequent expression loss of Inter-alpha-trypsin inhibitor heavy chain (ITIH) genes in multiple human solid tumors: A systematic expression analysis. *BMC Cancer* **2008**, *8*, 25. [CrossRef] [PubMed]

207. Jiang, X.; Bai, X.-Y.; Li, B.; Li, Y.; Xia, K.; Wang, M.; Li, S.; Wu, H. Plasma Inter-Alpha-Trypsin Inhibitor Heavy Chains H3 and H4 Serve as Novel Diagnostic Biomarkers in Human Colorectal Cancer. *Dis. Markers* **2019**, *2019*, 5069614. [CrossRef]

208. Chang, Q.-H.; Mao, T.; Tao, Y.; Dong, T.; Tang, X.-X.; Ge, G.-H.; Xu, Z.-J. Pan-cancer analysis identifies ITIH1 as a novel prognostic indicator for hepatocellular carcinoma. *Aging* **2021**, *13*, 11096–11119. [CrossRef] [PubMed]

209. Chong, F.K.; Lee, H.; Zhou, J.; Liu, S.-C.; Loh, M.C.S.; Wang, T.T.; Chan, S.P.; Smoot, D.T.; Ashktorab, H.; So, J.B.Y.; et al. ITIH3 is a potential biomarker for early detection of gastric cancer. *J. Proteome Res.* **2010**, *9*, 3671–3679. [CrossRef]

210. Sun, Y.; Jin, J.; Jing, H.; Lu, Y.; Zhu, Q.; Shu, C.; Zhang, Q.; Jing, D. ITIH4 is a novel serum biomarker for early gastric cancer diagnosis. *Clin. Chim. Acta* **2021**, *523*, 365–373. [PubMed]

211. Cheng, Z.; Lv, Y.; Pang, S.; Bai, R.; Wang, M.; Lin, S.; Xu, T.; Spalding, D.; Habib, N.; Xu, R. Kallistatin, a new and reliable biomarker for the diagnosis of liver cirrhosis. *Acta Pharmacol. Sin.* **2015**, *5*, 194–200. [PubMed]

212. Wang, J.; Wang, X.; Lin, S.; Chen, C.; Wang, C.; Ma, Q.; Jiang, B. Identification of kininogen-1 as a serum biomarker for the early detection of advanced colorectal adenoma and colorectal cancer. *PLoS ONE* **2013**, *8*, e70519. [CrossRef]

213. Yu, J.; Huang, Y.; Lin, C.; Li, X.; Fang, X.; Zhong, C.; Yuan, Y.; Zheng, S. Identification of Kininogen 1 as a Serum Protein Marker of Colorectal Adenoma in Patients with a Family History of Colorectal Cancer. *J. Cancer* **2018**, *9*, 540–547. [CrossRef] [PubMed]

214. Wang, W.; Wang, S.; Zhang, M. Evaluation of kininogen 1, osteopontin and α-1-antitrypsin in plasma, bronchoalveolar lavage fluid and urine for lung squamous cell carcinoma diagnosis. *Oncol. Lett.* **2020**, *19*, 2785–2792. [CrossRef] [PubMed]

215. Giataganja, E.-M.; Berdiaki, A.; Tsatsakis, A.; Tzanakakis, G.N.; Nikitovic, D. Lumican in Carcinogenesis—Revisited. *Biomolecules* **2021**, *11*, 1319. [CrossRef] [PubMed]

216. Pan, S.; Chen, R.; Brand, R.E.; Hawley, S.; Tamura, Y.; Gafken, P.R.; Milless, B.P.; Goodlett, D.R.; Rush, J.; Brentnall, T.A. Multiplex targeted proteomic assay for biomarker detection in plasma: A pancreatic cancer biomarker case study. *J. Proteome Res.* **2012**, *11*, 1937–1948. [CrossRef]

217. Appunni, S.; Anand, V.; Khandelwal, M.; Seth, A.; Mathur, S.; Sharma, A. Altered expression of small leucine-rich proteoglycans (Decorin, Biglycan and Lumican): Plausible diagnostic marker in urothelial carcinoma of bladder. *Tumor Biol.* **2017**, *39*, 1010428317699112. [CrossRef] [PubMed]

218. Rong, Y.; Jin, D.; Hou, C.; Hu, J.; Wu, W.; Ni, X.; Wang, D.; Lou, W. Proteomics analysis of serum protein profiling in pancreatic cancer patients by DIGE: Up-regulation of mannose-binding lectin 2 and myosin light chain kinase. *BMC Gastroenterol.* **2010**, *10*, 68. [CrossRef] [PubMed]

219. Su, C.; Lin, Y.; Cai, L.; Mao, Q.; Niu, J. Association between mannose-binding lectin variants, haplotypes and risk of hepatocellular carcinoma: A case-control study. *Sci. Rep.* **2016**, *6*, 32147. [CrossRef]

220. Ide, H.; Yamagishi, S.-I.; Lu, Y.; Sakamaki, K.; Nakajima, A.; Horiiuchi, A.; Kitamura, K.; Hisasue, S.-I.; Muto, S.; Yamaguchi, R.; et al. Circulating pigment epithelium-derived factor (PEDF) is associated with pathological grade of prostate cancer. *Anticancer Res.* **2015**, *35*, 1703–1708. [CrossRef]

221. Yang, Z.; Feng, J.; Xiao, L.; Chen, X.; Yao, Y.; Li, Y.; Tang, Y.; Zhang, S.; Lu, M.; Qian, Y.; et al. Tumor-Derived Pegaptanib Recognition Protein 2 Predicts Survival and Antitumor Immune Responses in Hepatocellular Carcinoma. *Hepatology* **2020**, *71*, 1626–1642. [CrossRef]

222. Holm, M.; Saraswat, M.; Joenväärá, S.; Ristimäki, A.; Håglund, C.; Renkonen, R. Colorectal cancer patients with different C-reactive protein levels and 5-year survival times can be differentiated with quantitative serum proteomics. *PLoS ONE* **2013**, *13*, e0195354. [CrossRef]

223. Kang, D.W.; Choi, K.-Y.; Min, D.S. Functional Regulation of Phospholipase D Expression in Cancer and Inflammation*. J. Biol. Chem.* **2014**, *289*, 22575–22582. [PubMed]

224. Tang, J.-H.; He, W.-J.; Huang, H.; Tan, C.-C.; Duan, Q.; Wang, K.-J.; Yuan, X.-Y.; Zhu, X.-J. Important roles of glycosylphosphatidylinositol (GPI)-specific phospholipase D and some GPI-anchored proteins in the pathogenesis of hepatocellular carcinoma. *Clin. Biochem.* **2009**, *42*, 400–407. [CrossRef]

225. Kwaan, H.C.; McMahon, B. The role of plasminogen-plasmin system in cancer. *Cancer Treat. Res.* **2009**, *148*, 43–66. [PubMed]

226. Bharadwaj, A.G.; Holloway, R.W.; Miller, V.A.; Waisman, D.M. Plasmin and Plasminogen System in the Tumor Microenvironment: Implications for Cancer Diagnosis, Prognosis, and Therapy. *Cancers* **2021**, *13*, 1838. [CrossRef]

227. Vecka, M.; Javová, M.; Vávrová, L.; Kodyková, J.; Macásek, J.; Urbánek, M.; Krechler, T.; Slaboková, J.; Muravská, A.; et al. Paraoxonase-1 (PON1) status in pancreatic cancer: Relation to clinical parameters. *Oncotarget* **2017**, *8*, 42817–42835. [CrossRef]

228. Zhang, J.; Yang, X.; Wei, L.; Tan, H.; Chen, J.; Li, W.; Chan, K.; Su, Y.; Zhao, L.; Hu, S.; et al. Improved diagnostic value by combining plasma PON1 level with tumor biomarkers in Colorectal Cancer patients. *J. Cancer* **2020**, *11*, 6491–6496. [CrossRef]

229. Ahn, S.B.; Sharma, S.; Mohamedali, A.; Mahboob, S.; Redmond, W.J.; Pascoveci, D.; Wu, J.X.; Zaw, T.; Adhikari, S.; Vaibhav, V.; et al. Potential early clinical stage colorectal cancer diagnosis using a proteomics blood test panel. *Clin. Proteom.* **2019**, *16*, 34. [CrossRef]
231. Afsar, C.U.; Gunaldis, M.; Okutular, Y.; Gedikbas, A.; Tiken, E.E.; Kahraman, S.; Karaca, F.; Ercolak, V.; Karabulut, M. Paraoxonase-1 and arylesterase activities in patients with colorectal cancer. *Int. J. Clin. Exp. Med.* 2015, 8, 21599–21604.

232. Akçay, M.N.; Yilmaz, I.; Polat, M.F.; Akçay, G. Serum paraoxonase levels in gastric cancer. *Hepatogastroenterology* 2003, 50 (Suppl. 2), cxxiii–cclxxv.

233. Schlesinger, M.; Bromann, I.; Lugassy, G. The complement system is defective in chronic lymphatic leukemia patients and in their healthy relatives. *Leukemia* 1996, 10, 1509–1513. [PubMed]

234. Uehara, S.; Fukuwazawa, Y.; Matuyama, T.; Gotoh, K. Role of Tyro 3, Axl, and Mer Receptors and Their Ligands (Gas 6, and Protein S) in Patients with Hepatocellular Carcinoma. *J. Cancer Ther.* 2017, 8, 112. [CrossRef]

235. Bushue, N.; Wan, Y.-J.Y. Retinoid pathway and cancer therapeutics. *Adv. Drug Deliv. Rev.* 2010, 62, 1285–1298. [CrossRef] [PubMed]

236. Hu, X.; Huang, W.; Wang, F.; Dai, Y.; Hu, X.; Yue, D.; Wang, S. Serum levels of retinol-binding protein 4 and the risk of non-small cell lung cancer: A case-control study. *Medicine* 2020, 99, e21254. [CrossRef] [PubMed] [PubMed]

237. Jiao, C.; Cui, L.; Ma, A.; Li, N.; Si, H. Elevated Serum Levels of Retinol-Binding Protein 4 Are Associated with Breast Cancer Risk: A Case-Control Study. *PLoS ONE* 2016, 11, e0167498.

238. Biaoxue, R.; Hua, L.; Wenlong, G.; Shuanying, Y. Increased serum amyloid A as potential diagnostic marker for lung cancer: A meta-analysis based on nine studies. *BMC Cancer* 2016, 16, 836. [CrossRef]

239. Malle, E.; Sodin-Semrl, S.; Kovacevic, A. Serum amyloid A: An acute-phase protein involved in tumour pathogenesis. *Cell. Mol. Life Sci.* 2009, 66, 9–26. [CrossRef]

240. Lin, H.; Tan, G.; Liu, Y.; Lin, S. The prognostic value of serum amyloid A in solid tumors: A meta-analysis. *Cancer Cell Int.* 2019, 19, 62. [CrossRef]

241. Levo, Y.; Wollner, S.; Treves, A.J. Serum amyloid P-component levels in patients with malignancy. *Scand. J. Immunol.* 1986, 24, 147–151. [CrossRef]

242. De Nunzio, C.; Lombardo, R.; Albisinni, S.; Gacci, M.; Tubaro, A. Serum levels of sex hormone binding globulin (SHBG) are not predictive of prostate cancer diagnosis and aggressiveness: Results from an Italian biopsy cohort. *Int. Braz J. Urol.* 2013, 39, 793–799. [CrossRef]

243. Cheng, C.-W.; Chang, C.-C.; Patria, Y.N.; Chang, R.-T.; Liu, Y.-R.; Li, F.-A.; Shih, H.-M.; Lin, C.-Y. Sex hormone-binding globulin (SHBG) is a potential early diagnostic biomarker for gastric cancer. *Cancer Med.* 2018, 7, 64–74. [CrossRef]

244. Gebhardt, C.; Németh, J.; Angel, P.; Hess, J. S100A8 and S100A9 in inflammation and cancer. *Biochem. Pharmacol.* 2006, 72, 1622–1631. [CrossRef] [PubMed]

245. Petsa, A.; Pergialiotis, V.; Konstantopoulos, P.; Katsichti, A.; Petrou, K.; Giannopoulos, A.; Botsis, D.; Perrea, D. Serum Calprotectin and Prealbumin Levels among Ovarian Cancer Patients Aged 30–45 Years. *Open J. Obstet. Gynecol.* 2017, 7, 303–311. [CrossRef]

246. Ni Bhriain, H.; Trovik, J.; Wik, E.; Stefansson, I.M.; Akslen, L.A.; Salvesen, H.B.; Staff, A.C. Plasma calprotectin concentrations in women with endometrial carcinoma. *Gynecol. Oncol.* 2009, 114, 491–495. [CrossRef] [PubMed] [PubMed]

247. Markowitz, J.; Carson, W.E. 3rd Review of S100A9 biology and its role in cancer. *Biochim. Biophys. Acta* 2013, 1835, 100–109. [PubMed]

248. Begum, F.D.; Høgdall, C.K.; Kjaer, S.K.; Christensen, L.; Blaakaer, J.; Bock, J.E.; Glud, E.; Heyer-Hansen, G.; Ring-Larsen, H.; Høgdall, E.V.S. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients. *Anticancer Res.* 2014, 34, 1981–1985.

249. Arellano-Garcia, M.E.; Li, R.; Liu, X.; Xie, Y.; Yan, X.; Loo, J.A.; Hu, S. Identification of tetranectin as a potential biomarker for metastatic oral cancer. *Int. J. Mol. Sci.* 2010, 11, 3106–3121. [CrossRef] [PubMed]

250. Terui, S.; Moriya, Y.; Yamamoto, H.; Koyama, Y. Thryoxine-binding globulin as a marker of liver tumors. *Cancer Detect. Prev.* 1987, 10, 371–378. [PubMed]

251. Sieg, A.; Schönprüf, A.; Seitz, H.K.; Kommerell, B. Thryoxine-binding globulin–not a tumor marker of hepatocellular cancer. *Z. Gastroenterol.* 1991, 29, 101–104.

252. Cui, S.-X.; Yu, X.-F.; Qu, X.-J. Roles and Signaling Pathways of Des-γ-Carboxyprothrombin in the Progression of Hepatocellular Carcinoma. *Cancer Invest.* 2016, 34, 459–464. [PubMed]

253. Yang, Y.; Li, G.; Lu, Z.; Liu, Y.; Kong, J.; Liu, J. Progression of Prothrombin Induced by Vitamin K Absence-II in Hepatocellular Carcinoma. *Front. Oncol.* 2021, 11, 4497. [PubMed]

254. Jain, S.; Gautam, V.; Naseem, S. Acute-phase proteins: As diagnostic tool. *J. Pharm. Bioallied Sci.* 2011, 3, 118–127. [CrossRef]

255. Lee, C.-C.; Ding, X.; Zhao, T.; Wu, L.; Perkins, S.; Du, H.; Yan, C. Transluyterin Stimulates Tumor Growth through Regulation of Tumor, Immune, and Endothelial Cells. *Int. J. Mol. Sci.* 2019, 202, 991–1002. [CrossRef] [PubMed]

256. Shimura, T.; Shibata, M.; Gonda, K.; Okayama, H.; Saito, M.; Momma, T.; Ohki, S.; Kono, K. Serum transthyretin level is associated with prognosis of patients with gastric cancer. *J. Surg. Res.* 2018, 227, 145–150. [CrossRef] [PubMed]

257. Gericke, B.; Riala, J.; Sehouli, J.; Haezel, S.; Konsgen, D.; Mustea, A.; Schweigert, F.J. Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients. *BMC Cancer* 2005, 5, 133. [CrossRef] [PubMed]

258. Malik, S.; Fu, L.; Juras, D.J.; Karmali, M.; Wong, B.Y.L.; Gozdzik, A.; Cole, D.E.C. Common variants of the vitamin D binding protein gene and adverse health outcomes. *Crit. Rev. Clin. Lab. Sci.* 2013, 50, 1–22. [CrossRef]

259. Speecakert, M.; Huang, G.; Delanghe, J.R.; Taes, Y.E.C. Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. *Clin. Chim. Acta* 2006, 372, 33–42. [PubMed]
